



Published in final edited form as:

Cell Rep. 2022 September 27; 40(13): 111426. doi:10.1016/j.celrep.2022.111426.

## Dopamine activates astrocytes in prefrontal cortex via $\alpha 1$ -adrenergic receptors

Silvia Pittolo<sup>1,7</sup>, Sae Yokoyama<sup>1,8</sup>, Drew D. Willoughby<sup>1,2</sup>, Charlotte R. Taylor<sup>1,2</sup>, Michael E. Reitman<sup>1,2</sup>, Vincent Tse<sup>1</sup>, Zhaofa Wu<sup>3,4</sup>, Roberto Etchenique<sup>5</sup>, Yulong Li<sup>3,4</sup>, Kira E. Poskanzer<sup>1,2,6,9,\*</sup>

<sup>1</sup>Department of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, CA, USA

<sup>2</sup>Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA, USA

<sup>3</sup>State Key Laboratory of Membrane Biology, Peking University School of Life Sciences, Beijing 100871, China

<sup>4</sup>Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China

<sup>5</sup>Departamento de Química Inorgánica, Analítica y Química Física, INQUIMAE, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CONICET, Intendente Güiraldes 2160, Ciudad Universitaria, Pabellón 2, C1428EGA, Buenos Aires, Argentina

<sup>6</sup>Kavli Institute for Fundamental Neuroscience, San Francisco, CA, USA

<sup>7</sup>Present address: Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rossle-Str. 10, 13125 Berlin, Germany

<sup>8</sup>Present address: Neuroscience Graduate Program, Princeton University, Princeton, NJ, USA

<sup>9</sup>Lead contact

### SUMMARY

The prefrontal cortex (PFC) is a hub for cognitive control, and dopamine profoundly influences its functions. In other brain regions, astrocytes sense diverse neurotransmitters and neuromodulators and, in turn, orchestrate regulation of neuroactive substances. However, basic physiology of PFC astrocytes, including which neuromodulatory signals they respond to and how they contribute to PFC function, is unclear. Here, we characterize divergent signaling signatures in mouse astrocytes of the PFC and primary sensory cortex, which show differential responsiveness to locomotion.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\*Correspondence: kira.poskanzer@ucsf.edu.

#### AUTHOR CONTRIBUTIONS

Conceptualization, S.P. and K.E.P.; methodology, S.P., S.Y., and K.E.P.; formal analysis, S.P.; investigation, S.P., S.Y., D.D.W., C.R.T., M.E.R., and V.T.; resources, Z.W., R.E., and Y.L.; writing - original draft, S.P. and K.E.P.; writing - review & editing, S.P. and K.E.P.; supervision, S.P. and K.E.P.; funding acquisition, S.P. and K.E.P.

#### SUPPLEMENTAL INFORMATION


Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2022.111426>.

#### DECLARATION OF INTERESTS

The authors declare no competing interests.

We find that PFC astrocytes express receptors for dopamine but are unresponsive through the Gs/Gi-cAMP pathway. Instead, fast calcium signals in PFC astrocytes are time locked to dopamine release and are mediated by  $\alpha$ 1-adrenergic receptors both *ex vivo* and *in vivo*. Further, we describe dopamine-triggered regulation of extracellular ATP at PFC astrocyte territories. Thus, we identify astrocytes as active players in dopaminergic signaling in the PFC, contributing to PFC function through neuromodulator receptor crosstalk.

## Graphical Abstract



## In brief

Pittolo et al. demonstrate that the neuromodulator dopamine targets astrocytes, a type of brain cell, via receptors specific to another neuromodulator—norepinephrine. This study provides groundwork on how dopamine affects non-neuronal brain cells and suggests that crosstalk between neuromodulatory pathways occurs *in vivo*, with possible clinical implications.

## INTRODUCTION

The prefrontal cortex (PFC) is a higher order association cortex that integrates sensory and cognitive information from other brain areas to execute behavior (Fuster et al., 2000). The PFC is involved in fundamental and diverse processes, including working memory and attention (Funahashi et al., 1989; Fuster and Alexander, 1971; Kesner et al., 1996), behavioral flexibility and planning (Dias et al., 1996; Ragozzino et al., 1999),

and processing of stress, fear, and emotions (George et al., 1995; Hariri et al., 2003; Kim et al., 2003; Milad and Quirk, 2002). Despite its importance, many aspects of PFC function remain poorly understood. For instance, whether persistent activity of individual PFC neurons or rather network dynamics underlie the ability of the PFC to hold information over multi-second delays during working memory tasks is subject of current debate (Barbosa et al., 2020; Cavanagh et al., 2018; Constantinidis et al., 2018; Inagaki et al., 2019; Park et al., 2019; Spaak et al., 2017).

While prefrontal circuits are fundamental for the top-down control of behavior, ascending arousal systems—including the mesocortical dopamine (DA) pathway—are so essential to PFC executive functions that their disruption recapitulates PFC lesions (Brozoski et al., 1979). Dopaminergic projections to the PFC are particularly sensitive to stressful and aversive stimuli (Abercrombie et al., 1989; Lammel et al., 2012; Thierry et al., 1976; Vander Weele et al., 2018). However, how both phasic and tonic temporal patterns of DA play specific roles in PFC computations is unclear (Lohani et al., 2019), with evidence for bidirectional or opposing effects on the excitability of prefrontal neuron subtypes (Anastasiades et al., 2019; Chen et al., 2007; Gao and Goldman-Rakic, 2003; Gao et al., 2003; Huang et al., 2004; Kröner et al., 2007; Matsuda et al., 2006; Seamans et al., 2001; Vijayraghavan et al., 2007), which ultimately contribute to complex patterns of circuit activity underlying PFC functions.

Astrocytes—the most abundant non-neuronal brain cells—are well positioned to process neuronal signals as they express receptors for neurotransmitters and neuromodulators (Porter and McCarthy, 1997) and have wide territories, each encompassing thousands of synapses (Bushong et al., 2002). Astrocytes are in a bidirectional dialogue with neurons, sensing neuronal activity through G protein-coupled receptors (GPCRs) (Kofuji and Araque, 2021), internally computing through calcium ( $\text{Ca}^{2+}$ ) and cAMP (Oe et al., 2020; Srinivasan et al., 2016), and regulating neuroactive substances such as glutamate (Bezzi et al., 2004; Yang et al., 2019) and ATP (Cao et al., 2013; Pascual et al., 2005; Zhang et al., 2003) that influence synaptic plasticity and network connectivity (Panatier et al., 2011; Perea and Araque, 2007; Poskanzer and Yuste, 2016). Impaired function of PFC astrocytes can cause depressive (Banasar and Duman, 2008; Cao et al., 2013; John et al., 2012; Lee et al., 2013) or autism-like behaviors (Wang et al., 2021) and interfere with working memory (Lima et al., 2014; Mederos et al., 2021; Petrelli et al., 2020; Sardinha et al., 2017). However, the mechanisms underlying astrocytic contributions to the PFC are still largely unexplored.

Here, we use *in vivo* two-photon (2P) imaging, fiber photometry (FP), and *ex vivo* imaging of  $\text{Ca}^{2+}$ , cAMP, neuromodulators, and ATP to explore astrocyte signals in the PFC. We first characterize  $\text{Ca}^{2+}$  dynamics of PFC astrocytes *in vivo* and compare them with primary visual cortex (V1) astrocytes. We find that PFC astrocytes display unique spatiotemporal signals and lack responsiveness to locomotion as opposed to sensory cortex (Paukert et al., 2014; Wang et al., 2019). We demonstrate that PFC astrocytes express DA receptors (DRs) but signal through fast, sustained  $\text{Ca}^{2+}$  mobilizations rather than canonical DR  $\text{G}_s/\text{G}_i$ -cAMP pathways. Unexpectedly, we find that DA in the PFC elicits astrocyte activation through the  $\text{G}_q$ -coupled  $\alpha 1$ -adrenergic receptor (AR) both in acute slices and *in vivo*. Finally, we show that PFC astrocytes can regulate extracellular ATP ( $\text{ATP}_E$ ) in response to DA. Together,

our data demonstrate that PFC astrocytes sense neuromodulators and behavioral stimuli differently than sensory cortical astrocytes. By exploring the physiology of PFC astrocytes, we uncover functional crosstalk between DA and receptors for norepinephrine (NE).

## RESULTS

### PFC astrocytes exhibit single-cell restricted Ca<sup>2+</sup> activity

Since PFC is an association cortical area (Fuster et al., 2000), we hypothesized that astrocyte Ca<sup>2+</sup> in the PFC may have unique properties compared with primary sensory cortex, where population-level bursts of activity are well documented (Bekar et al., 2008; Ding et al., 2013; Slezak et al., 2019; Srinivasan et al., 2016; Wang et al., 2019). To test this, we compared spontaneous astrocyte Ca<sup>2+</sup> activity in the PFC and V1 using 2P microscopy in head-fixed mice. We implanted either a GRIN lens (Levene et al., 2004) over the PFC or a cranial window over V1 in mice expressing Lck-GCaMP6f (Figure 1A) (Shigetomi et al., 2010; Srinivasan et al., 2016) under the astrocyte-specific promoter *GfaABC1D*. GRIN lens positioning was confirmed postmortem, and GFAP staining confirmed low astrocyte reactivity around the implant (Figure S1).

Using event-based image analyses (Wang et al., 2019), the largest astrocyte Ca<sup>2+</sup> signals in the PFC often appeared the size of a single astrocyte (~50 × 50 μm; Figures 1B and 1C, top), whereas the population-level, burst-like events in V1 span the entire imaging field (300 × 300 μm; Figures 1B and 1C, bottom; Slezak et al., 2019; Srinivasan et al., 2016; Wang et al., 2019). We focused on these larger events (>1,000 μm<sup>2</sup>) for comparison (Figures 1D–1H) and found that while astrocyte Ca<sup>2+</sup> events occur at the same rate in the PFC and V1 (Figure 1D), they are smaller (Figure 1E) and last longer (Figure 1F) in the PFC. We found that Ca<sup>2+</sup> events in the PFC are less synchronous with other PFC events (Figure 1G) but repeat more at the same locations in the imaging field compared with those in V1 (Figure 1H). Although less obvious, smaller Ca<sup>2+</sup> events (<1,000 μm<sup>2</sup>) also differ between the PFC and V1 (Figures S1C–S1G). These data indicate that Ca<sup>2+</sup> dynamics may be driven by different mechanisms depending on brain region and suggest that PFC astrocytes may play different functional roles than in primary sensory cortex.

### Population-level astrocyte Ca<sup>2+</sup> activity in PFC is not tightly linked to locomotion

Since burst-like astrocyte Ca<sup>2+</sup> in V1 is locomotion driven (Paukert et al., 2014; Slezak et al., 2019; Wang et al., 2019), we next wondered whether differences in Ca<sup>2+</sup> in the PFC and V1 were due to differences in responses to locomotion (Video S1). To examine this, we aligned population-level astrocyte Ca<sup>2+</sup> traces to locomotion onsets (Figures 1J–1K and S1H–S1I). Average astrocyte Ca<sup>2+</sup> in V1 significantly increases soon after locomotion onset (Figure 1K, left, green; Paukert et al., 2014; Slezak et al., 2019). By plotting the distribution of time of maximum change in Ca<sup>2+</sup> (Figure 1K, right), we observe a peak 6–9 s after locomotion onset. In contrast, PFC astrocytes did not exhibit significant and sustained Ca<sup>2+</sup> increases at locomotion onset, and no clear peak for maximum change across trials is evident (Figure 1K, red). These results indicate that PFC astrocytes are not activated by locomotion on average, although we do not exclude the possibility that a few astrocytes or domains are locomotion linked. To explore whether Ca<sup>2+</sup> in PFC astrocytes

is instead involved in locomotion generation, we aligned locomotion traces to  $\text{Ca}^{2+}$  event onset (Figures 1L–1M and S1J–S1K) and found no times when speed significantly deviated from average (Figure 1M, left, red). When mice moved, the maximum speed was equally distributed over the time window around  $\text{Ca}^{2+}$  event onsets (Figure 1M, right), suggesting that PFC  $\text{Ca}^{2+}$  activity is unlinked from locomotion. In contrast,  $\text{Ca}^{2+}$ -aligned locomotion analysis in V1 shows that speed increases starting at  $-5.1$  s before  $\text{Ca}^{2+}$  event onset and until  $2.2$  s after and peaks  $-1.1$  s before  $\text{Ca}^{2+}$  onset (Figure 1M, left, green), in accordance with previous observations (Figures 1J and 1K (Paukert et al., 2014; Slezak et al., 2019)). These results indicate that astrocyte activity in the PFC differs significantly from that in V1 both in  $\text{Ca}^{2+}$  event dynamics and their relationship with locomotion.

### PFC astrocytes express DRs

Because burst-like astrocyte population dynamics are mediated by NE (Bekar et al., 2008; Ding et al., 2013; Paukert et al., 2014) and PFC astrocytes do not display bursting (Figures 1B and 1C), we wondered whether DA—a neuromodulatory input for PFC neurons (Brozoski et al., 1979; Thierry et al., 1976)—is involved in PFC astrocyte  $\text{Ca}^{2+}$  activity *in vivo*. To explore this, we examined DR expression in PFC astrocytes by crossing transgenic reporter lines *Drd1a*-tdTomato (Shuen et al., 2008) or *Drd2*-EGFP (Gong et al., 2003) to the astrocyte-specific reporter lines *Aldh111*-EGFP (Tsai et al., 2012) or *Aldh111*-tdTomato (Gong et al., 2003) (Figure 2A). We immunostained for the fluorophores and determined colocalization in cell somata across PFC layers (Figures 2B–2D and S2A), finding that  $13\% \pm 1\%$  of all *Aldh111*<sup>+</sup> cells colocalize with  $\text{D}_1$  and  $14\% \pm 1\%$  colocalize with  $\text{D}_2$  (Figure 2C). Conversely,  $18\% \pm 2\%$  of all  $\text{D}_1$ <sup>+</sup> cells and  $41\% \pm 3\%$  of all  $\text{D}_2$ <sup>+</sup> cells are *Aldh111*<sup>+</sup> (Figure 2D). For both receptors, co-localization with *Aldh111* was maximal in layer 1, consistent with mostly neuronal projections rather than somata in the most superficial layer. These results demonstrate expression of  $\text{D}_1$  and  $\text{D}_2$  in PFC astrocytes, suggesting that PFC astrocytes may respond specifically to DA, as in other brain regions (Chai et al., 2017; Corkrum et al., 2020; Cui et al., 2016; Fischer et al., 2020; Jennings et al., 2017; Xin et al., 2019).

### Direct DR stimulation does not recruit cAMP intracellular signaling

$\text{D}_1$ -like ( $\text{D}_{1/5}$ ) and  $\text{D}_2$ -like ( $\text{D}_{2/3/4}$ ) receptors (hereafter  $\text{D}_1\text{R}$  and  $\text{D}_2\text{R}$ ) are canonically coupled adenylate cyclase (AC) through  $\text{G}_s$  and  $\text{G}_i$ -proteins, respectively. To test whether these receptors in PFC astrocytes lead to changes in cAMP, we expressed the fluorescent cAMP reporter Pink Flamindo (Harada et al., 2017) in PFC astrocytes and performed acute slice experiments (Figure 2E) while pharmacologically targeting DRs (Figures 2F and 2G). We blocked possible contributions from neighboring  $\text{D}_1\text{R}$ - and  $\text{D}_2\text{R}$ -expressing neurons by inhibiting action potentials (tetrodotoxin [TTX]) and preventing neuron-to-astrocyte signaling (multi-drug cocktail; STAR Methods). We bath applied  $10 \mu\text{M}$  DA to reflect physiological levels (Figure 2F, top left) and did not observe changes in average Pink Flamindo fluorescence (Figure 2G). However, because  $\text{D}_1\text{R}$  and  $\text{D}_2\text{R}$  have opposing effects on AC, DA could, in principle, both stimulate and inhibit cAMP. We searched at the single-cell level for increases or decreases in cAMP and still did not observe changes with DA (Figure S2B).

To distinguish between contributions of  $G_s$  and  $G_i$  signaling, we next directly activated either D1R or D2R with subtype-specific agonists (D1R: SKF81297, 10  $\mu$ M; D2R: quinpirole, 10  $\mu$ M) and imaged cAMP (Figure 2F, middle-bottom left). Again, we found no change in average cAMP with either drug (Figure 2G). To confirm that Pink Flamindo detects cAMP changes, we followed each experiment with bath application of the AC activator forskolin (10  $\mu$ M; Figure 2F, right). Forskolin led to consistent increases in Pink Flamindo fluorescence relative to both baseline and drug treatment (Figures 2G and S2B), which was comparable to forskolin stimulation in naive slices (-TTX and drug cocktail; Figure S2C). We confirmed that these results were not due to slice-to-slice variability (Figures 2G and S2B) or cell-to-cell differences in Pink Flamindo expression (Figure S2D), indicating that neither DA nor DR subtype-specific agonists induce detectable changes downstream of  $G_s$  or  $G_i$  effector proteins in PFC astrocytes.

### DA activates PFC astrocyte $Ca^{2+}$ signals via cell-surface ARs

To test whether DA mobilizes intracellular  $Ca^{2+}$  rather than cAMP in PFC astrocytes—and may be mediating *in vivo*  $Ca^{2+}$  activity (Figure 1)—we expressed GCaMP6f in PFC astrocytes using viruses (Figures 3A and 3B) and carried out bath-application experiments in acute slices, blocking neuronal activity as above. DA bath-application caused an increase in  $Ca^{2+}$  event frequency compared with baseline (Video S2; Figures 3C, 3D, 3E, and S3B, pink). In contrast, application of D1R and D2R agonists (SKF38393 and quinpirole, 10  $\mu$ M) had no discernible effect on  $Ca^{2+}$  (Figures 3E, yellow, and S3A, top left). To test whether DRs are engaged in DA-dependent increases in  $Ca^{2+}$ , we next bath applied DA in the presence of DR antagonists SCH23390 and sulpiride and observed partial inhibition of  $Ca^{2+}$  dynamics (Figure S3A, top right), although no significant decrease in event rate was seen compared with DA alone (Figure 3E, blue).

Since the effect of DA on  $Ca^{2+}$  is minimally inhibited by DR antagonists, we next tested whether the robust response to DA is mediated by GPCRs by adding DA to slices from mice genetically lacking IP<sub>3</sub>R2 (Li et al., 2005), the main intracellular receptor downstream of GPCRs in astrocytes mediating intracellular  $Ca^{2+}$  release (Petraevic et al., 2008; Zhang et al., 2014). In these slices, we observed significant inhibition of  $Ca^{2+}$  mobilization by DA (Figures 3E, gray, and S3A, bottom left), suggesting that PFC astrocytes indeed rely on GPCRs to mediate the  $Ca^{2+}$  response. Because DA can act on ARs in neurons (Alachkar et al., 2010; Ciliz et al., 2014; Cornil et al., 2002; Guiard et al., 2008; Marek and Aghajanian, 1999; Özkan et al., 2017), we next carried out DA application in the presence of broad-spectrum AR antagonists ( $\alpha$ 1/ $\alpha$ 2: phentolamine;  $\beta$ :propranolol; 10 $\mu$ M). In contrast to DR antagonists, blocking ARs completely abolished DA-mediated increase in  $Ca^{2+}$  activity (Figures 3E, green, and S3A, bottom right).

Because  $Ca^{2+}$  activity by bathed DA had a slow onset and was sensitive to AR inhibitors, we thought that DA may be transformed to NE, a one-step enzymatic product of DA (Kirshner, 1957). To confirm that PFC astrocytes were indeed responding to DA and not NE, we imaged acute PFC slices in which the fluorescent sensor GRAB<sub>NE</sub> (Feng et al., 2019) was expressed throughout the tissue (Figure 3F) and bath applied either DA or NE. DA did not induce a significant change in GRAB<sub>NE</sub>, in contrast to a large response to NE (Figure 3G),

suggesting that the response to DA mediated by ARs (Figure 3E) is not linked to conversion of DA to NE. Lastly, we tested whether DA induced  $\text{Ca}^{2+}$  via GPCR signaling from the plasma membrane, or via intracellular compartments, since GPCR signaling can occur via internal organelles (Calebiro et al., 2009; Irannejad et al., 2013; Kotowski et al., 2011) and DR antagonists display low membrane permeability (Dos Santos Pereira et al., 2014). To do this, we imaged PFC astrocyte  $\text{Ca}^{2+}$  (using Fluo-4) in organic cation transporter 3 knockout mice ( $\text{OCT3}^{-/-}$ ; Figures 3H and S3C), in which intracellular transport of monoamines is blocked (Amphoux et al., 2006; Cui et al., 2009; Duan and Wang, 2010; Zwart et al., 2001). DA bath application in these slices (Figure 3I, left) led to a robust increase in Fluo-4 fluorescence (Figure 3I, right), suggesting that DA acts on cell-surface GPCRs in PFC astrocytes.

### Physiological concentrations of DA evoke fast $\text{Ca}^{2+}$ transients in PFC astrocytes

The previous experiments demonstrated that PFC astrocytes respond to continuous DA application with slow-onset  $\text{Ca}^{2+}$  transients. We next explored whether astrocytes can be engaged by acute stimuli better reflecting physiological DA dynamics. To do so, we used one-photon (1P) activation of a caged DA (RuBi-DA; Figures 4A and 4B) (Araya et al., 2013) to achieve fast release and mimic volume transmission (Agnati et al., 1995; Banerjee et al., 2020), the main modality of PFC DA release. We validated our light-stimulation protocol with the fluorescent DA sensor dLight (Patriarchi et al., 2018) by comparing a DA dose-response curve (Figures 4C and S4A) with photoactivation of RuBi-DA (Figures 4D and S4B, left). We estimate that uncaging released  $\sim 2 \mu\text{M}$  DA (Figure 4E), matching DA levels detected by voltammetry in the PFC *in vivo* (Garris and Wightman, 1994) and DA concentration estimates near release sites in other areas (Courtney and Ford, 2014; Patriarchi et al., 2018).

To understand how single PFC astrocytes respond to temporally controlled DA release, we uncaged RuBi-DA in slices with GCaMP-expressing astrocytes (Figure 4F, top; Video S3) while blocking neurons as above. We drew borders around each cell (Figure 4F, bottom) and detected  $\text{Ca}^{2+}$  events (Figures 4G–4I) to monitor the area within cells recruited over time (Figures 4J–4L). In control conditions (no RuBi-DA; Figures 4G and 4H, left), most cells (91%) were inactive throughout the trial, and similar numbers increased or decreased  $\text{Ca}^{2+}$  activity around the light pulse (4%). In RuBi-DA (Figures 4G and 4H, right), most cells across cortical layers responded to uncaging with increased (62%), rather than decreased (4%), activity. In individual cells, events were more abundant, larger, and lasted longer following light stimulation in RuBi-DA but not in controls (Figure 4I). These results were not affected by the pharmacological cocktail used since all features of  $\text{Ca}^{2+}$  events were unchanged compared with naive slices (Figures S4C and S4D).

Overall,  $\text{Ca}^{2+}$  mobilization in individual astrocytes (Figures 4K and 4K) was induced with a short onset time (8.6 s; Figure 4L, left) and short duration (9.9 s; Figure 4K, middle), whereas the area of the cell recruited varied considerably among cells (49%; Figure 4L, right). These results were not affected by our single-cell delineation method, as no correlation between cell size and area of cell recruited by DA was seen (Figure S4E).

These data demonstrate that astrocytes respond acutely to physiological DA levels with fast, transient  $\text{Ca}^{2+}$  dynamics covering variable astrocyte territories.

### PFC astrocytes require $\alpha 1$ -AR signaling for DA response

We next photoreleased DA on PFC slices treated with subtype-specific inhibitors of DRs or ARs (Figure 5A; Video S4). As before (Figure 4), we observed an increase in  $\text{Ca}^{2+}$  following uncaging of RuBi-DA alone (Figures 5B and 5C, pink; control). Antagonizing D1R or D2R did not occlude the response to DA (Figures 5B and 5C), in accordance with bath-application data (Figure 3E) and further supporting the idea that DRs are not involved in the recruitment of PFC astrocytes by DA. Next, we tested the contribution of all AR subtypes ( $\alpha 1$ ,  $\alpha 2$ , and  $\beta$ ) to DA-mediated  $\text{Ca}^{2+}$  activity and found that only inhibition of  $\alpha 1$ -AR prevented  $\text{Ca}^{2+}$  mobilization after DA photorelease (Figures 5B and 5C). We also measured astrocyte activity using different metrics (Figures S5A and S5B) and found no change from the above results. Overall, these data suggest that fast, volume transmissionlike release of DA at physiological concentrations recruits PFC astrocytes via  $\alpha 1$ -ARs.

### DA evokes $\text{Ca}^{2+}$ signals in PFC astrocytes via $\alpha 1$ -ARs *in vivo*

To test whether DA input to the PFC induces astrocyte activity *in vivo*, we carried out dual-color FP recordings using viral expression of the red-shifted  $\text{Ca}^{2+}$  sensor jR-GECO1b and the DA sensor dLight (Figures 6A and S6E). Because aversive stimuli such as foot shock (Thierry et al., 1976), tail shock (Abercrombie et al., 1989), and tail pinch (Vander Weele et al., 2018) activate the mesocortical DA system, we used an aversive tail-lift stimulus (Hurst and West, 2010) to increase DA levels in the PFC. Using this experimental paradigm and monitoring extracellular DA, we found that this was indeed the case (Figure 6A, green). jR-GECO1b signals also showed large astrocyte  $\text{Ca}^{2+}$  transients during the tail lift (Figure 6A, pink). Aligning transients from these channels showed that jR-GECO closely followed dLight (Figures 6B, 6C, and S6A). Cross-correlation indicated that dLight precedes the jR-GECO signal by 1.4 s (Figure 6D), suggesting that extracellular DA contributes to the PFC astrocyte  $\text{Ca}^{2+}$  that follows aversive stimuli.

Because aversion also releases NE in the PFC (Gresch et al., 1994), we next sought to describe any contribution of NE to this close relationship between DA and astrocyte  $\text{Ca}^{2+}$  *in vivo*. To do this, we carried out dual-color FP experiments after injection of DSP4 (Figure 6E), a toxin that specifically ablates locus coeruleus (LC) projection fibers (Bekar et al., 2008; Ding et al., 2013; Fritschy and Grzanna, 1989), the main source of PFC NE. We confirmed that DSP4 reduced LC fibers in the PFC by NE transporter (NET) immunostaining after treatment (Figure 6F) and again compared dLight and jR-GECO. DA signal amplitude in response to the aversion paradigm was unchanged in astrocytes of NE-depleted mice compared with controls (Figure S6B, left), supporting the selectivity of the toxin in targeting LC fibers (Berger et al., 1974). In addition, while we observed a decrease in astrocyte  $\text{Ca}^{2+}$  amplitude (Figure S6B, right)—consistent with NE effects elsewhere (Bekar et al., 2008; Ding et al., 2013; Gordon et al., 2005; Paukert et al., 2014)— $\text{Ca}^{2+}$  transients co-occurring with dLight transients remained evident after NE depletion (Figure S6A, middle row). These  $\text{Ca}^{2+}$  signals were longer (18 s; Figure S6C) and occurred with longer lag after dLight (2.6 s; Figure S6D) compared with untreated animals (duration



7 s, lag 1.4 s), which may be explained by slower DA uptake in the absence of NET (Morón et al., 2002; Sesack et al., 1998). These results indicate that mesocortical DA can recruit PFC astrocytes during an aversive stimulation, independent of LC input.

To test the possible crosstalk of DA and  $\alpha 1$ -ARs *in vivo*, we next compared responses to aversive stimulation in mice treated with DSP4 before and after injection of the bioavailable  $\alpha 1$ -AR antagonist prazosin (Figures 6G and 6H). While dLight signals in response to aversion were maintained after prazosin (Figure 6G, left),  $\text{Ca}^{2+}$  dynamics were significantly reduced (Figure 6G, right) and did not follow DA dynamics (Figure 6H). Together, these data suggest that  $\alpha 1$ -AR signaling accounts for the bulk of the astrocyte  $\text{Ca}^{2+}$  response to DA in PFC *in vivo*.

### DA increases $\text{ATP}_E$ at PFC astrocytes

DA stimulates ATP release from *nucleus accumbens* astrocytes (Corkrum et al., 2020). To test whether  $\alpha 1$ -AR-mediated activation of PFC astrocytes by DA leads to  $\text{ATP}_E$  mobilization, we performed acute slice experiments on astrocytes expressing a fluorescent ATP sensor (GRAB<sub>ATP</sub>; Figures 7A and 7B; Wu et al., 2021). We determined the response dynamics of the sensor by bathing on exogenous ATP (50  $\mu\text{M}$ ; Figures 7B and 7C). Continuous ATP stimulation led to an increased event rate (Figure 7D), with events whose size matched the territory of individual astrocytes and could be detected during the entire course of the ATP application (Figure 7E), showing that GRAB<sub>ATP</sub> reliably detects  $\text{ATP}_E$  over the entire astrocyte surface for prolonged periods.

We next repeated GRAB<sub>ATP</sub> experiments while bath applying DA (10  $\mu\text{M}$ ; Figures 7F–7H) and blocking neuronal contributions as above (without PPADS and CGS 15943 to avoid occluding GRAB<sub>ATP</sub> fluorescence changes; STAR Methods). DA induced mobilization of  $\text{ATP}_E$  (Figure 7H) and increased ATP event frequency (Figure 7I). These sparse, DA-induced events lasted ~30 s and did not encompass the entire astrocyte territory (Figure 7J), indicating that ATP is increased at specific cellular locations at PFC astrocytes in response to DA. When adding doxazosin before each recording to inhibit  $\alpha 1$ -ARs (Figure 7K), the frequency of  $\text{ATP}_E$  events after addition of DA no longer increased (Figures 7M–7N), but the area and duration of the spontaneous events were similar to those observed with DA alone (Figures 7L and 7O), supporting the concept that  $\alpha 1$ -ARs are important for DA signaling that leads to  $\text{ATP}_E$  increases. Although we do not rule out the contribution of other cell types to this phenomenon, this relationship between DA signaling and  $\text{ATP}_E$  may contribute to regulation of synaptic transmission in PFC.

## DISCUSSION

### PFC astrocyte function *in vivo*

Astrocytes play active roles in computation and behavior, including in the PFC (Mederos et al., 2021). We find that PFC astrocytes differ in neurophysiology from those in sensory cortex (Figure 1). They are activated with different spatiotemporal patterns of intracellular  $\text{Ca}^{2+}$  (Figure 1) and when animals are exposed to aversive stimuli (Figure 6) but not in response to locomotion (Figure 1). These results are consistent with PFC neuronal

network involvement in stress processing (Abercrombie et al., 1989; Lammel et al., 2012; Rosenkranz and Grace, 2001; Thierry et al., 1976; Vander Weele et al., 2018), with changes in astrocytes following stress (Abbink et al., 2019; Bender et al., 2020; Murphy-Royal et al., 2020; Simard et al., 2018), and with divergent transcriptomic, morphological, and cellular signaling landscapes in astrocytes of different brain areas (Batiuk et al., 2020; Chai et al., 2017; Khakh and Sofroniew, 2015; Xin et al., 2019), to support the hypothesis that astrocytes serve specific functions in the PFC.

### DA actions on PFC astrocytes: Sustained and heterogeneous responses

Compared with subcortical areas (Abercrombie et al., 1989; Garris and Wightman, 1994), spatial diffusion and temporal availability of DA in the PFC are extended due to faster firing (Lammel et al., 2008) and lower reuptake rates (Sesack et al., 1998), resulting in complex effects on PFC circuits (Lohani et al., 2019). Astrocytes respond with  $\text{Ca}^{2+}$  to DA in non-cortical brain areas (Chai et al., 2017; Corkrum et al., 2020; Cui et al., 2016; Fischer et al., 2020; Jennings et al., 2017; Xin et al., 2019), and our study expands this knowledge to the PFC, demonstrating further that astrocytes can respond to both continuous (Figure 3) and phasic release (Figure 4) of DA. The different dynamics of PFC astrocyte  $\text{Ca}^{2+}$  observed in response to these two modes of DA delivery suggest a possible mechanism by which astrocytes discern between tonic and phasic DA signals, which are integral to PFC function. Since in *ex vivo* experiments we blocked action potentials and neuronally released molecules known to bind astrocytic GPCRs, our data demonstrate that PFC astrocytes respond to DA directly, i.e., independently of neuronal activation. This indicates that astrocytes actively contribute to the dopaminergic control of the PFC.

Our uncaging data (Figure 4) show that, even in the absence of neuronal DA responses, rapid release of physiological levels of DA recruits astrocyte responses in seconds, which are sustained for tens of seconds in most cells. Individual astrocyte responses, rather than population-wide activity, demonstrate that the extent of subcellular locations engaged in  $\text{Ca}^{2+}$  signaling following DA release differs across PFC astrocytes. These observations suggest that astrocytes may be involved in regulation of sustained activity and contribute to local PFC computations in a cell-specific manner.

### DA actions on PFC astrocytes: Receptors and signaling pathways

Our results demonstrating that DA acting on PFC astrocytes recruits  $\text{Ca}^{2+}$  (Figures 3 and 4) rather than cAMP (Figure 2) are in contrast with neuronal research showing that DA activates  $G_s/G_i$ -cAMP pathways canonically ascribed to D1R and D2R (Lee et al., 2021; Muntean et al., 2018; Nomura et al., 2014; Yapo et al., 2017) but in agreement with evidence that DA activates the astrocytic  $G_q$ -IP<sub>3</sub>- $\text{Ca}^{2+}$  pathway elsewhere (Chai et al., 2017; Corkrum et al., 2020; Cui et al., 2016; Fischer et al., 2020; Jennings et al., 2017; Xin et al., 2019). These results suggest differential expression of signaling machinery components across cell types. However, pharmacology data (Figures 3, 5, and 6) support the idea that lack of cAMP mobilization is due to DA acting on PFC astrocytes exclusively through  $\alpha$ 1-AR, even though PFC astrocytes express D<sub>1</sub> and D<sub>2</sub> (Figure 2). Indeed, our data that PFC astrocytes respond to DA by  $\alpha$ 1-ARs differ from previous astrocytic research in other brain regions, in which DA changes  $\text{Ca}^{2+}$  via DRs (Corkrum et al., 2020; Fischer et al.,

2020; Jennings et al., 2017). However, it is consistent with studies of neuronal activation by DA showing that DR agonists or antagonists are unable to reproduce or prevent effects of DA (Cilz et al., 2014; Cornil and Ball, 2008; Cornil et al., 2002; Guiard et al., 2008; Marek and Aghajanian, 1999; Nicola and Malenka, 1997; Özkan et al., 2017). Further, our data could help reconcile apparently contradictory findings whereby different modes of DA activation (i.e., DA versus synthetic agonists) lead to contrasting results in astrocytes even within brain regions (Corkrum et al., 2020; D'Ascenzo et al., 2007). For instance, dorsoventral or layer-specific gradients of ventral tegmental area (VTA)/LC innervation or DR/AR expression in hippocampus (Edelmann and Lessmann, 2018) could have influenced responses observed by Jennings et al. (2017), whereby lower local expression of DRs in *stratum lacunosum-moleculare* could have allowed AR-mediated DA responses to take over, explaining a lack of sensitivity to DR antagonists. Similarly, because the transcriptomic, morphological, and signaling landscape of astrocytes can diverge across cortical layers or brain areas (Batiuk et al., 2020; Chai et al., 2017; Lanjakornsiripan et al., 2018; Xin et al., 2019), region- or subregion-specific patterns of innervation and receptor expression could favor different mechanisms of DA activation and explain the lack of activation by D1/D2 agonists in some studies (Chai et al., 2017; D'Ascenzo et al., 2007) and the lack of inhibition by DR antagonists in others (Jennings et al., 2017).

### DA/ $\alpha$ 1-AR promiscuity

We show that astrocytic DA signaling is subject to receptor promiscuity, a finding supported by research reporting that neuronal effects of DA could not be reproduced with DA-selective agonists (Cilz et al., 2014; Nicola and Malenka, 1997; Özkan et al., 2017) or could be prevented by  $\alpha$ -AR, but not DR, antagonists (Cilz et al., 2014; Cornil et al., 2002; Guiard et al., 2008; Marek and Aghajanian, 1999; Özkan et al., 2017). Further, many levels of interaction between dopaminergic and noradrenergic systems have been documented in PFC: DA and NE are co-released by LC fibers (Devoto et al., 2005), DA uptake occurs mainly by NET (Morón et al., 2002), and sub- or supra-threshold stimulation of both systems leads to detrimental outcomes on PFC performance (Arnsten et al., 2012). Together, this indicates that DA may interact with the noradrenergic system at receptor and signal transduction levels on PFC astrocytes. However, despite likely acting through the same astrocytic receptors, DA and NE show markedly different  $\text{Ca}^{2+}$  mobilization signatures: DA evokes high-frequency events small in amplitude and duration (Figure 3), while NE causes big amplitude and short duration events (Pankratov and Lalo, 2015). Thus, DA-AR crosstalk does not implicate information loss, as astrocytes may implement different effects downstream of specific inputs, through combinations of receptors recruited, their stoichiometry, and positions relative to effectors.

How this promiscuity originates at the receptor level is an exciting follow-up area. For example, does DA bind directly to  $\alpha$ 1-ARs and stimulate  $\text{Ca}^{2+}$  independently from DRs, or does DA induce a physical interaction between the bound DR and  $\alpha$ 1-AR, which then drives downstream  $\text{Ca}^{2+}$ ? While radioligand binding studies indicate that non-specific interaction of DA with  $\alpha$ 1-AR only occurs at sub-mM concentrations (Proudman and Baker, 2021; Steinberg and Bilezikian, 1982), D<sub>1</sub> and  $\alpha$ 1-AR co-localize on PFC dendrites and may undergo co-trafficking (Mitrano et al., 2014). Further, co-immunoprecipitation,

bioluminescence resonance energy transfer (BRET)/fluorescence resonance energy transfer (FRET) sensors, and proximity-ligation assays support the idea that DRs can form functional heteromeric complexes with ARs (González et al., 2012; Rebois et al., 2012).

Many drugs for psychiatric disorders such as depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), and schizophrenia target multiple monoamine systems (Stanford and Heal, 2019). Astrocytes have been linked to ADHD (Nagai et al., 2019), and methylphenidate—a therapy for ADHD—increases both DA and NE concentration by blocking DAT and NET (Berridge et al., 2006). Our results highlight open questions about these treatments: are both neuromodulators needed for therapeutic outcomes, or are both involved in adverse effects? Do DA and NE act differently on neurons or non-neuronal cells? Are both DRs and ARs required to transduce DA signals in astrocytes, and would drugs that specifically target this interaction achieve better outcomes and minimize side effects? Clarifying the interactions between DA and ARs will be key for understanding treatments involving both catecholamine systems.

### **PFC DA, astrocytes, and ATP**

ATP is released by astrocytes in other brain areas in response to DA (Corkrum et al., 2020) and other neurotransmitters (Gordon et al., 2005; Lalo et al., 2014; Pougnet et al., 2014) and can lead to synaptic depression (Corkrum et al., 2020; Martin-Fernandez et al., 2017; Pascual et al., 2005; Zhang et al., 2003). Because we observe regulation of ATP<sub>E</sub> in response to DA during neuronal blockade (Figure 7), and PFC astrocytes can release ATP (Cao et al., 2013), DA may favor suppression of PFC activity over long timescales through astrocyte-derived ATP, such as during delay periods of working memory tasks. Here, DA induces spatially restricted patterns of ATP<sub>E</sub>, suggesting that astrocytes could depress activity of specific synapses located within their territories. Future work could explore whether PFC astrocytes regulate ATP<sub>E</sub> at defined neuronal subtypes or synapses to coordinate specific microcircuits.

### **Limitations of the study**

We show that PFC astrocytes differ from V1 astrocytes in relation to locomotion, as an example of a simple behavior. Further studies are needed to explore astrocytic function relative to complex behaviors and test whether our results are unique to the PFC. While the present work shows that ARs are required as a functional link between DA and PFC astrocytes, DA could also target non-astrocytic ARs, and further work could clarify whether this crosstalk occurs in other cell types or brain regions.

## **STAR★METHODS**

### **RESOURCE AVAILABILITY**

**Lead contact**—Further information and requests for resources and reagents may be directed to and will be fulfilled by the lead contact, Dr. Kira Poskanzer (kira.poskanzer@ucsf.edu).

**Materials availability**—This study did not generate new reagents.

### Data and code availability

- All data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Animals**—Experiments were carried out as detailed below, using young adult for *ex vivo* (P27–54) or adult mice (P50–130) for *in vivo* experiments, in accordance with protocols approved by the University of California, San Francisco Institutional Animal Care and Use Committee (IACUC). Animals were housed in a 12:12 light-dark cycle with food and water provided *ad libitum*. Male and female mice were used whenever available. For *in vivo* experiments following surgery, all animals were singly housed to protect implants and given additional enrichment. Animals were included when sensor expression was sufficient to visualize sensor dynamics; animals were excluded from uncaging experiments when no response to dopamine uncaging was detected upon a test uncaging stimulus. Transgenic mice used in this study were Lck-GCaMP6<sup>fl/fl</sup> mice (Srinivasan et al., 2016) and *Aldh111*-Cre/ERT2 mice (Srinivasan et al., 2016) from the Khakh lab (UCLA, USA), *Drd1a*-tdTomato (Shuen et al., 2008) and *Drd2*-EGFP (Gong et al., 2003) from the Bender lab (UCSF, USA), *Aldh111*-EGFP and *Aldh111*-tdTomato (Gong et al., 2003) from JAX (USA), *Itp2*-deficient mice (IP<sub>3</sub>R2<sup>-/-</sup>) (Li et al., 2005) from Dr. Katsuhiko Mikoshiba (RIKEN, Japan) and *Slc22a3*-deficient mice (OCT3<sup>-/-</sup>) (Zwart et al., 2001) from the Irannejad lab (UCSF, USA).

## METHOD DETAILS

**Surgical procedures**—For viral expression in *ex vivo* experiments, neonatal mice (P0–4) on C57Bl/6 or Swiss background were anesthetized on ice for 2 min before injecting viral vectors (*AAV5-GfaABC<sub>1</sub>D-GCaMP6f* [1.4–5.42e<sup>13</sup>; all titers in GC/mL], *AAV9-hGfap-pinkFlamingo* [6.6e<sup>13</sup>], *AAV9-hSyn-NE2.1* [5.72e<sup>13</sup>], *AAV9-CAG-dLight1.2* [9.5e<sup>15</sup>], or *AAV9-hSyn-ATP1.0* [4.89e<sup>13</sup>]). Pups were placed on a digital stereotax and coordinates were zeroed at the middle point along the line connecting the eyeballs. Two injection sites over PFC were chosen at 0.25–0.34 mm lateral, and 1 and 1.4 mm caudal. At each injection site, 30–100nL of virus were injected at a rate of 3–5nL/s at two depths (0.7–0.85, and 0.9–1 mm ventral) using a microsyringe pump (UMP-3, World Precision Instruments).

For *in vivo* 2P imaging, we expressed Lck-GCaMP in astrocytes of adult mice (P50–130), either by crossing Lck-GCaMP6<sup>fl/fl</sup> mice to *Aldh111*-Cre/ERT2 (Srinivasan et al., 2016) and treating them with tamoxifen (0.1mg/kg, i.p., for 5 consecutive days, 4–6 weeks before imaging), or via viral vectors (see below) in C57Bl/6 mice. For FP, we expressed dLight and astrocytic jR-GECO1b via viral vectors (see below) in C57Bl/6 mice (P60–90). Before surgical procedures, adult mice were administered dexamethasone (5mg/kg, s.c.) and anesthetized with isoflurane, and a 1- or 3-mm diameter craniotomy was created over PFC (+1.7–1.8 mm rostral, +0.5 mm lateral from bregma) or visual cortex (–3.5mm caudal, +1.2 mm lateral from bregma). Viral vectors (*AAV5-GfaABC<sub>1</sub>D-Lck-GCaMP6f-SV40* [1.4–

5.42e<sup>13</sup>], *AAV5-hSyn-dLight1.2* [4e<sup>12</sup>], *AAV9-GfaABC<sub>1</sub>D-Lck-jRGECO1b* [2.24e<sup>14</sup>]) were delivered using a microsyringe pump (100–600 nL, 30–60 nL/min) before implanting optical devices. For 2P imaging in PFC, after careful removal of meninges, a GRIN lens (1-mm diameter, 4.38-mm length, WDA 100, 860 nm, Inscopix) was slowly lowered to –2.4mm ventral; for 2P imaging in V1, a cranial window was placed above the tissue; a custom-made titanium headplate was then attached to the skull. For FP in PFC, a fiber optic cannula (Mono Fiberoptic Cannula, 400µm core, 430nm, 0.48 NA, 2.8mm length, Doric Lenses) was implanted at the same depth as GRIN lenses. All imaging devices were secured in place using dental cement (C&B Metabond, Parkell). Post-operative care included administration of 0.05mg/kg buprenorphine and 5mg/kg carprofen. Mice were allowed a minimum of 14 days to recover, then habituated to head-fixation on a circular treadmill or to fiberoptic coupling in a freely moving arena prior to experiments.

***In vivo* 2P imaging and locomotion**—2P imaging experiments were carried out on an upright microscope (Bruker Ultima IV) equipped with a Ti:Sa laser (MaiTai, SpectraPhysics). The laser beam intensity was modulated using a Pockels cell (Conoptics) and scanned with linear galvanometers. Images were acquired with a 16×, 0.8 N.A. (Nikon) or a 20×, 1.0 N.A. (XLUMPLFLN-W, Olympus) water-immersion objective via photomultiplier tubes (Hamamatsu) using PrairieView (Bruker) software. For GCaMP imaging, 950 nm excitation and a 515/30 emission filter were used. Mice were head-fixed on a circular treadmill and Ca<sup>2+</sup> activity was recorded at ~1.7 Hz frame rate from putative PFC or V1 cortex, at 512 × 512 pixels and ~0.6mm/px resolution. Locomotion speed was monitored using an optoswitch (50mA, 2V; OPB800L55, TT Electronics, Newark) connected to a microcontroller board (Arduino Uno R3, Arduino) and acquired at 1KHz simultaneously with 2P imaging using PrairieView.

***Ex vivo* 2P imaging and uncaging**—Coronal, acute PFC slices (300-µm thick) from P27–54 mice were cut with a vibratome (VT 1200, Leica) in ice-cold cutting solution containing (in mM) 27 NaHCO<sub>3</sub>, 1.5 NaH<sub>2</sub>PO<sub>4</sub>, 222 sucrose, 2.6 KCl, 2 MgSO<sub>4</sub>, 2 CaCl<sub>2</sub>. Slices were transferred to pre-heated, continuously aerated (95% O<sub>2</sub>/5% CO<sub>2</sub>) standard artificial cerebrospinal fluid (ACSF) containing (in mM) 123 NaCl, 26 NaHCO<sub>3</sub>, 1 NaH<sub>2</sub>PO<sub>4</sub>, 10 dextrose, 3 KCl, 2 MgSO<sub>4</sub>, 2 CaCl<sub>2</sub>. Younger mice were sliced in the same solutions for dLight (P18–28) and GRAB<sub>NE</sub> (P24–35) experiments, and one P19 IP<sub>3</sub>R2<sup>-/-</sup> experiment (otherwise P31–36). Slices were kept at room temperature until imaging, and experiments performed at 37°C. To block neuronal action potentials and neuron-to-astrocyte-communication during imaging, at least 10 min before experiments recirculating standard ACSF was switched to a multi-drug cocktail mix, containing (in µM) 1 TTX, 100 LY341495, 1 CGP 55845, 2 AM251, 1 CGS 15943, 100 PPADS, 5 Ipratropium, unless otherwise stated.

Slice recordings were done in coronal sections above medial prefrontal cortex, and the imaging area was ~0.6–0.8 mm × 0.8 mm over prelimbic and infralimbic areas, with the top part of the imaging area corresponding to the midline, thus spanning all cortical layers. Images were acquired from putative PL-IL cortex in PFC slices at a minimum depth of 50 µm, using the same setup as for *in vivo* 2P imaging or a custom-made upright microscope

and ScanImage software, at 1.42–1.53 Hz frame rate, 512 × 512 pixels and 1.04–1.61 μm/px resolution. Fluorophores were excited at (in nm) 950–980 (GCaMP), 1040 (Pink Flamindo), 980 (dLight), 920 (GRAB<sub>NE</sub> and GRAB<sub>ATP</sub>). Emission was collected with a 515/30 or 525/50 filter for green and a 605/15 or 600/40 filter for red fluorophores. For bath-application experiments, a 5-min baseline was recorded to monitor spontaneous activity, after which neuromodulators were added along with a fluorescent dye (Alexa Fluor 594 Hydrazide) to assess the time at which drugs reached the imaging field (except for Pink Flamindo due to spectral overlap).

For RuBi-DA uncaging, a fiber optic cannula (400-μm core, 0.39 NA; CFM14L10, ThorLabs) was coupled to a compatible fiber optic (M79L005, ThorLabs) and a blue LED (470 nm; M470F3, ThorLabs), and placed adjacent to the imaging field using a micromanipulator (MX160R, Siskiyou). Illumination (3 pulses, 100-ms duration, 50-ms intervals) was triggered using the imaging software (PrairieView, Bruker) connected to the LED-driver cube (LEDD1B, ThorLabs). Light power was 2–4 mW.

For pharmacology experiments in Figure 2, we note that Quinpirole is a full agonist at all D<sub>2</sub>-like DRs (D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub>). However, because all D<sub>2</sub>-like receptors are coupled to G<sub>s</sub> proteins—thus canonically linked to increases in cAMP levels—we assumed that this widely used D<sub>2</sub> agonist would cause similar changes in cAMP regardless of the receptor subtype. Likewise, SKF81297 is a full agonist at all D<sub>1</sub>-like receptors (D<sub>1</sub> and D<sub>5</sub>). Because no response to D<sub>1R</sub>/D<sub>2R</sub> stimulation was detected, we did not explore the contribution of individual receptor subtypes further.

**Fiber photometry recordings**—FP experiments were carried out using an RZ10 FP processor equipped with Lux integrated 405, 465, and 560-nm LEDs and photosensors (Tucker-Davis Technologies). Animals implanted for FP were placed in a freely moving arena in which the mouse was able to move in all directions, after coupling to low autofluorescence fiberoptic patchcords (400-μm core, 0.57 NA; Doric Lenses) connected to photosensors through a rotary joint (Doric Lenses). FP fluorescence signals were recorded for 10 min, during which tail lifts were performed every minute. For a tail lift stimulation, the experimenter held and lifted the tail of the animal until its hind paws disconnected from the ground; after that the tail was released. With this experimental paradigm, no pain or harm is caused to the animal. After baseline recordings, animals were treated with DSP4 (50 mg/kg, i.p., 2 injections 2 days apart) and recorded again 4 days after the first DSP4 administration. Following DSP4 recordings, animals were injected with Prazosin (5 mg/kg, i.p.) and recorded again 20 min later.

**Immunohistochemistry**—Mice were intracardially perfused with 4% PFA, brains were then collected, immersed in 4% PFA overnight at 4°C and switched to 30% sucrose for two days before being frozen on dry ice and stored at –80°C. Brains were sliced coronally (40-μm thick) on a cryostat, and slices stored in cryoprotectant at –20°C until staining. Slices were washed 3x in PBS for 5 min, then permeabilized for 30 min with 0.01% Triton X- in PBS. Slices were next washed with 10% NGS (Invitrogen) for 1 h and incubated overnight with primary antibodies at 4°C in 2% NGS. Slices were next rinsed 3x in PBS before incubating for 2 h at room temperature with secondary antibodies, then washed 3x in

PBS for 5 min before slide-mounting and coverslipping using Fluoromount with DAPI. To stain for EGFP and tdTomato in D1, D2 and Aldh111 colocalization experiments, primary antibodies used were rat anti-mCherry (1:1000, Thermo Fisher Scientific) and chicken anti-GFP (1:3000, Aves Lab) in 2% NGS. Secondary antibodies used were goat anti-rat Alexa Fluor 555 (1:1000) and goat anti-chicken Alexa Fluor 488 (1:1000). To stain brain tissue from GRIN lens experiments, primary antibodies used were rat anti-GFAP (1:1000, Thermo Fisher Scientific) and chicken anti-GFP (1:3000, Aves Lab) for Lck-GCaMP. To stain for dLight and jR-GECO1b in sections from FP experiments, primary antibodies used were rat anti-mCherry (1:1000, Thermo Fisher Scientific) and chicken anti-GFP (1:3000, Abcam). Secondary antibodies used were goat anti-rat Alexa Fluor 555 (1:1000, Thermo Fisher Scientific) and goat anti-chicken Alexa Fluor 488 (1:1000, Thermo Fisher Scientific). For NET staining, sections were incubated for 1 h with a secondary mouse block (AffiniPure Fab Fragment IgG, 30  $\mu\text{g}/\text{mL}$ , Jackson ImmunoResearch) before primary antibody mouse anti-NET (1:100, MAb Technologies), and secondary antibody goat anti-mouse Alexa Fluor 555 (1:1000, Thermo Fisher Scientific). Z-stacks or whole-brain images were acquired at 40x or 2x using a Keyence BZ-X800 fluorescence microscope and stitched with Keyence Analysis Software.

## QUANTIFICATION AND STATISTICAL ANALYSIS

**Colocalization cell counts**—To estimate colocalization, 3 slices/mouse were chosen at +1.8, +1.7 and +1.6 mm from bregma, and tiled z-stack images were acquired on a spinning disk confocal (Zeiss) at PFC spanning cortical layers 1–6. Colocalization counts of tdTomato<sup>+</sup> and EGFP<sup>+</sup> cells were performed using Cell Counter in Fiji (ImageJ).

**2P image and data analysis**—When necessary, videos were preprocessed by registering images using the ImageJ plugin MoCo (Dubbs et al., 2016). Cell maps for Pink Flamingo, GRAB<sub>ATP</sub>, and uncaging experiments were drawn using the interactive wand segmentation tool (SCF-MPI-CBG plugin).

**AQuA event detection:** Ca<sup>2+</sup> and ATP 2P image sequences were analyzed using AQuA software (Wang et al., 2019) and custom MATLAB (Mathworks) code. Signal detection thresholds were adjusted for each video to account for differences in noise levels after manually checking for accurate AQuA-detection. Events were thresholded post-detection at 25  $\mu\text{m}^2$  and 2 s for *ex vivo*, or 50  $\mu\text{m}^2$  and 2 s for *in vivo* Ca<sup>2+</sup> imaging, and at 50  $\mu\text{m}^2$  and 2.5 s for GRAB<sub>ATP</sub> imaging. Event count was quantified using the onset of each event as detected by AQuA. Area is defined as the footprint occupied by an event over its entire lifetime. Number of co-occurring events is calculated as the number of events co-existing temporally anywhere in the imaging field with a given event. Number of co-localized events is calculated as the number of events having comparable size (0.5–2x) and overlapping spatially with a given event.

**In vivo 2P imaging and locomotion analysis:** For locomotion-aligned astrocyte Ca<sup>2+</sup> analysis, only locomotion bouts longer than 2 s and starting more than 10 s after the previous locomotion bout ended were considered (Figure S1H). Population-wide mean Ca<sup>2+</sup> traces (Figure 1I) were obtained by normalizing the fluorescence of each AQuA-detected



event as  $(F - F_{\min}) / (F_{\max} - F_{\min})$  and then averaging across events. For max  $\text{Ca}^{2+}$  (Figure 1K), changes in normalized fluorescence were thresholded at 0.1 to exclude noise. For astrocyte  $\text{Ca}^{2+}$ -aligned locomotion analysis (Figure 1L), astrocyte  $\text{Ca}^{2+}$  event  $dF/F$  was used and all locomotion bouts were considered. Locomotion speed was calculated as cm/s.

**Bath-applied DA analysis:** For bathed-DA experiments,  $\text{Ca}^{2+}$  event rate was calculated as counts of AQuA-event onsets in 5-s bins ( $\text{Ca}^{2+}$ , and events for the post-treatment condition (Figure 3E) were analyzed over a 30-s window centered at 90-s post drug or at the time point when the event rate exceeds baseline (6 STD of event rate at baseline). We then calculated the peak onset as the last local minimum before the peak, and—to overcome false positives due to noise—we constrained the local minima to be below the 6 STD threshold for peak detection. At baseline (Figure S3B) we used a 60-s window to account for low number of spontaneous events. For  $\text{GRAB}_{\text{ATP}}$ , events were analyzed over 300-s windows, immediately before (basal) and 90-s post drug. The 300-s window (for the post-drug condition) was started 90-s after the delivery of the drug since we wanted to probe ATP events that would follow DA-induced  $\text{Ca}^{2+}$  events, which—in bath application experiments (Figure 3)—started ~90s after drug delivery.

**Single-cell ex vivo uncaging analysis:** Classification of cell activity around uncaging was done based on counts of AQuA-event onsets in the 60-s before versus 60-s after uncaging ( $t = 0$ ). Event features (count, area, duration) were averaged by cell and slice using the same temporal windows. Traces for the % of cell area active were obtained as the overall number of pixels/frame occupied by AQuA-detected events within an individual astrocyte (cell territories were defined by cell maps, see above). Traces were analyzed with custom-written code in MATLAB to find peak times, amplitudes (max % cell surface active) and duration (FWHM). Latency to peak onset after uncaging (delay) was obtained as the first time point above threshold (6 STD of the pre-uncaging activity).

**ROI-based analysis:** Pink Flamindo,  $\text{GRAB}_{\text{NE}}$  and dLight videos were analyzed using ROI-based approaches in ImageJ. Changes in fluorescence intensity were calculated as  $(F - F_0) / F_0$  ( $dF/F$ ), where  $F_0$  is the average intensity of the first 20–30 frames. For  $\text{GRAB}_{\text{NE}}$ ,  $dF/F$  values were extracted as 20-s means at 50 s before (pre-drug) or 340 s after compound addition. Fluo-4 videos from  $\text{OCT3}^{-/-}$  KO experiments were analyzed using CalTracer 3 Beta (Poskanzer and Yuste, 2016),  $dF/F$  traces extracted from the automatically detected cell somata, and identified peaks checked manually for accurate detection before extracting duration and latency. Traces'  $dF/F$ s were then obtained as 5-s means at 100 s before or after DA addition based on average peak latencies. Data for the dLight dose-response curves were fit to a Hill equation ( $y = a + (b - a) / (1 + 10^{((c - x) * d)})$ ), and DA concentrations released by RuBi-DA uncaging were extrapolated from the obtained fit function based on changes in dLight fluorescence after uncaging.

**Pink Flamindo analysis:** For Pink Flamindo experiments, background fluorescence was subtracted from raw fluorescence traces. To identify steady-state increases or decreases in fluorescence, traces were smoothened using a moving average and then fit using a modified Boltzmann's sigmoidal equation  $y = a + (b - a) / (1 + \exp((c - x) / d))$ , where  $a$  is the bottom,

b is the top, c is the inflection point and d is the slope, using a nonlinear least squares algorithm (Levenberg-Marquardt) in MATLAB. Fit constraints were  $(b-a) > \text{noise}$ ,  $\text{slope} < 10$ , and inflection point at  $x > 0$ . Cells where the sigmoid fit of the trace in response to Forskolin did not converge were excluded from all previous analyses. Cells with high noise ( $> 0.1$  dF/F) or drift (when change in dF/F before drug application exceeded noise) were removed. Noise was calculated as 3 STD at baseline. Average dF/F values (Figure 2G) were then extracted as 20-s means at 40 s before (control) or 240 s after compound addition (drug/ Forskolin) from original traces.

**Fiber photometry analysis**—FP data were preprocessed by downsampling and subtraction of the isosbestic channel linear fit (as in <https://www.tdt.com/docs/sdk/offline-data-analysis/offline-data-python/FibPhoEpoC Averaging>), detrended to correct bleaching, and dF/F calculated as above ( $F_0$  obtained at 0–15 s). Traces were then denoised using an IIR lowpass filter in MATLAB (cutoff frequency 1Hz, steepness 0.95). Transients in jR-GECO1b traces were detected using the ‘findpeaks’ function in MATLAB (applied over normalized traces, with minimum peak height and prominence set to 25% and at a minimum distance of 20 s, according to the timing of the tail lift stimulation protocol. All trials/animals were analyzed using the same parameters for peak detection.) Transient onsets were determined as the timepoints where the first derivative exceeded 1 STD. Then, dLight and jR-GECO1b traces were extracted in 40-s windows centered at onsets, and the cross-correlation function calculated from the extracted traces with a 6-s maximum lag to obtain the latency to maximum cross-correlation. Response amplitudes (Figures 6C and 6G) were calculated for each detected peak as change in dF/F between trace average before onset and trace maximum after onset.

**Statistics**—Statistics used for each dataset and their results, as well as the exact value of n and whether n represents cells, animals or replicates, and the definition of center, dispersion and precision are detailed in the figure legends. To compare one group of data with a hypothesized mean value we used a one-sample t test or sign test (Wilcoxon) as appropriate after a normality test. When comparing two unpaired groups, we used the two-sample, unpaired t test or the Wilcoxon rank-sum test (Mann-Whitney) as appropriate after a normality test. When comparing two paired groups of data, we used the paired t test or the Wilcoxon signed rank test after checking for normality on the difference between groups. Normality was checked using the Anderson-Darling test. When comparing treatments for three or more groups (Figures 3E and 3G) we used one-way Anova or the Kruskal-Wallis test after testing for equal variances using the Levene test (quadratic). For Pink Flamindo data (Figure 2G), we used the non-parametric Friedman test for paired data after the Levene test to compare within conditions (control, drug, Forskolin), and one-way Anova or Kruskal-Wallis test after the Levene test to compare across treatments. Multiple comparisons in Figure 5 were not corrected *post hoc* to minimize type II errors (i.e., to avoid increasing the rate of false negatives; in a false negative, pre-to post-uncaging values would be erroneously considered non-significantly different from each other). All statistical tests are two-tailed unless otherwise stated in the figure legend (Figure S5B).

Statistical significance for time-series data was computed using the shuffle test with custom-written code in MATLAB. Data pairs were selected as a reference value (trace mean from  $t < 0$  or the entire time window analyzed) and a given time point in the time-series ( $t > 0$  or all timepoints in the window). Data from the two groups were pairwise shuffled for 10,000 repetitions to calculate the difference between the two populations, the significance level  $\alpha$  for rejecting  $H_0$  was set to 0.01, and Bonferroni correction was applied to account for multiple comparisons.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

The authors are grateful to the Poskanzer lab for helpful discussions, especially Michelle Cahill for *ex vivo* analysis. We thank the Bender lab (UCSF) and Yuste lab (Columbia University) for reagent assistance, Victoria Cheung in the Feinberg lab (UCSF) for FP set up, Hajime Hirase (University of Copenhagen) for Pink Flamindo, and Jennifer Thompson for administrative support. K.E.P. is supported by NIH R01NS099254, R01MH121446, and R21DA048497 and NSF CAREER 1942360. S.P. is supported by the EU under the Horizon 2020 Marie Skłodowska Curie Actions project ASTRALIS, GA 839561. M.E.R. was supported by the UCSF Genentech Fellowship. R.E. is a member of CONICET.

## REFERENCES

- Abbink MR, van Deijk ALF, Heine VM, Verheijen MH, and Korosi A (2019). The involvement of astrocytes in early-life adversity induced programming of the brain. *Glia* 67, 1637–1653. 10.1002/glia.23625. [PubMed: 31038797]
- Abercrombie ED, Keefe KA, DiFrischia DS, and Zigmond MJ (1989). Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. *J. Neurochem* 52, 1655–1658. 10.1111/j.1471-4159.1989.tb09224.x. [PubMed: 2709017]
- Agnati LF, Zoli M, Stromberg I, and Fuxe K (1995). Intercellular communication in the brain: wiring versus volume transmission. *Neuroscience* 69, 711–726. 10.1016/0306-4522(95)00308-6. [PubMed: 8596642]
- Alachkar A, Brotchie JM, and Jones OT (2010). Binding of dopamine and 3-methoxytyramine as 1-DOPA metabolites to human  $\alpha$ 2-adrenergic and dopaminergic receptors. *Neurosci. Res* 67, 245–249. 10.1016/j.neures.2010.03.008. [PubMed: 20302892]
- Amphoux A, Vialou V, Drescher E, Bruss M, La Cour CM, Rochat C, Millan MJ, Giros B, Bonisch H, and Gautron S (2006). Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. *Neuropharmacology* 50, 941–952. 10.1016/j.neuropharm.2006.01.005. [PubMed: 16581093]
- Anastasiades PG, Boada C, and Carter AG (2019). Cell-type-specific D1 dopamine receptor modulation of projection neurons and interneurons in the prefrontal cortex. *Cereb. Cortex* 29, 3224–3242. 10.1093/cercor/bhy299. [PubMed: 30566584]
- Araya R, Andino-Pavlovsky V, Yuste R, and Etchenique R (2013). Two-photon optical interrogation of individual dendritic spines with caged dopamine. *ACS Chem. Neurosci* 4, 1163–1167. 10.1021/cn4000692. [PubMed: 23672485]
- Arnsten AFT, Wang MJ, and Paspalas CD (2012). Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. *Neuron* 76, 223–239. 10.1016/j.neuron.2012.08.038. [PubMed: 23040817]
- Banasr M, and Duman RS (2008). Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. *Biol. Psychiatry* 64, 863–870. 10.1016/j.biopsych.2008.06.008. [PubMed: 18639237]

- Banerjee A, Lee J, Nemcova P, Liu C, and Kaeser PS (2020). Synapto-tagmin-1 is the Ca<sup>2+</sup> sensor for fast striatal dopamine release. *Elife* 9, e58359. 10.7554/elife.58359. [PubMed: 32490813]
- Barbosa J, Stein H, Martinez RL, Galan-Gadea A, Li S, Dalmau J, Adam KCS, Valls-Sole J, Constantinidis C, and Compte A (2020). Interplay between persistent activity and activity-silent dynamics in the prefrontal cortex underlies serial biases in working memory. *Nat. Neurosci* 23, 1016–1024. 10.1038/s41593-020-0644-4. [PubMed: 32572236]
- Batiuk MY, Martirosyan A, Wahis J, de Vin F, Marneffe C, Kusserow C, Koeppen J, Viana JF, Oliveira JF, Voet T, et al. (2020). Identification of region-specific astrocyte subtypes at single cell resolution. *Nat. Commun* 11, 1220. 10.1038/s41467-019-14198-8. [PubMed: 32139688]
- Bekar LK, He W, and Nedergaard M (2008). Locuscoeruleusalpha-adrenergic-mediated activation of cortical astrocytes in vivo. *Cereb. Cortex* 18, 2789–2795. 10.1093/cercor/bhn040. [PubMed: 18372288]
- Bender CL, Sun X, Farooq M, Yang Q, Davison C, Maroteaux M, Huang Y-S, Ishikawa Y, and Liu SJ (2020). Emotional stress induces structural plasticity in bergmann glial cells via an AC5-CPEB3-GluA1 pathway. *J. Neurosci* 40, 3374–3384. 10.1523/jneurosci.0013-19.2020. [PubMed: 32229518]
- Berger B, Tassin JP, Blanc G, Moyné MA, and Thierry AM (1974). Histochemical confirmation for dopaminergic innervation of the rat cerebral cortex after destruction of the noradrenergic ascending pathways. *Brain Res.* 81, 332–337. 10.1016/0006-8993(74)90948-2. [PubMed: 4373130]
- Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B, Hamilton C, and Spencer RC (2006). Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. *Biol. Psychiatry* 60, 1111–1120. 10.1016/j.biopsych.2006.04.022. [PubMed: 16806100]
- Bezzi P, Gunderson V, Galbete JL, Seifert G, Steinhäuser C, Pilati E, and Volterra A (2004). Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. *Nat. Neurosci* 7, 613–620. 10.1038/nn1246. [PubMed: 15156145]
- Brozoski TJ, Brown RM, Rosvold HE, and Goldman PS (1979). Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. *Science* 205, 929–932. 10.1126/science.112679. [PubMed: 112679]
- Bushong EA, Martone ME, Jones YZ, and Ellisman MH (2002). Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J. Neurosci* 22, 183–192. 10.1523/jneurosci.22-01-00183.2002. [PubMed: 11756501]
- Calebiro D, Nikolaev VO, Gagliani MC, de Filippis T, Dees C, Tacchetti C, Persani L, and Lohse MJ (2009). Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. *PLoS Biol.* 7, e1000172. 10.1371/journal.pbio.1000172. [PubMed: 19688034]
- Cao X, Li L-P, Wang Q, Wu Q, Hu H-H, Zhang M, Fang Y-Y, Zhang J, Li S-J, Xiong W-C, et al. (2013). Astrocyte-derived ATP modulates depressive-like behaviors. *Nat. Med* 19, 773–777. 10.1038/nm.3162. [PubMed: 23644515]
- Cavanagh SE, Towers JP, Wallis JD, Hunt LT, and Kennerley SW (2018). Reconciling persistent and dynamic hypotheses of working memory coding in prefrontal cortex. *Nat. Commun* 9, 3498. 10.1038/s41467-018-05873-3. [PubMed: 30158519]
- Chai H, Diaz-Castro B, Shigetomi E, Monte E, Oceau JC, Yu X, Cohn W, Rajendran PS, Vondriska TM, Whitelegge JP, et al. (2017). Neural circuit-specialized astrocytes: transcriptomic, proteomic, morphological, and functional evidence. *Neuron* 95, 531–549.e9. 10.1016/j.neuron.2017.06.029. [PubMed: 28712653]
- Chen L, Bohanick JD, Nishihara M, Seamans JK, and Yang CR (2007). Dopamine D1/5 receptor-mediated long-term potentiation of intrinsic excitability in rat prefrontal cortical neurons: Ca<sup>2+</sup>-dependent intracellular signaling. *J. Neurophysiol* 97, 2448–2464. 10.1152/jn.00317.2006. [PubMed: 17229830]
- Cilz NI, Kurada L, Hu B, and Lei S (2014). Dopaminergic modulation of GABAergic transmission in the entorhinal cortex: concerted roles of  $\alpha$ 1 adrenoceptors, inward rectifier K<sup>+</sup>, and T-type Ca<sup>2+</sup> channels. *Cereb. Cortex* 24, 3195–3208. 10.1093/cercor/bht177. [PubMed: 23843440]

- Constantinidis C, Funahashi S, Lee D, Murray JD, Qi X-L, Wang M, and Arnsten AFT (2018). Persistent spiking activity underlies working memory. *J. Neurosci* 38, 7020–7028. 10.1523/jneurosci.2486-17.2018. [PubMed: 30089641]
- Corkrum M, Covelo A, Lines J, Bellocchio L, Pisansky M, Loke K, Quintana R, Rothwell PE, Lujan R, Marsicano G, et al. (2020). Dopamine-evoked synaptic regulation in the nucleus accumbens requires astrocyte activity. *Neuron* 105, 1036–1047.e5. 10.1016/j.neuron.2019.12.026. [PubMed: 31954621]
- Cornil CA, and Ball GF (2008). Interplay among catecholamine systems: dopamine binds to  $\alpha_2$ -adrenergic receptors in birds and mammals. *J. Comp. Neurol* 511, 610–627. 10.1002/cne.21861. [PubMed: 18924139]
- Cornil CA, Balthazart J, Motte P, Massotte L, and Seutin V (2002). Dopamine activates noradrenergic receptors in the preoptic area. *J. Neurosci* 22, 9320–9330. 10.1523/jneurosci.22-21-09320.2002. [PubMed: 12417657]
- Courtney NA, and Ford CP (2014). The timing of dopamine- and noradrenaline-mediated transmission reflects underlying differences in the extent of spillover and pooling. *J. Neurosci* 34, 7645–7656. 10.1523/jneurosci.0166-14.2014. [PubMed: 24872568]
- Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, and Tieu K (2009). The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. *Proc. Natl. Acad. Sci. USA* 106, 8043–8048. 10.1073/pnas.0900358106. [PubMed: 19416912]
- Cui Q, Pitt JE, Pamukcu A, Poulin J-F, Mabrouk OS, Fiske MP, Fan B, Augustine EC, Young KA, Kennedy RT, et al. (2016). Blunted mGluR activation disinhibits striatopallidal transmission in parkinsonian mice. *Cell Rep.* 17, 2431–2444. 10.1016/j.celrep.2016.10.087. [PubMed: 27880915]
- D’Ascenzo M, Fellin T, Terunuma M, Revilla-Sanchez R, Meaney DF, Auberson YP, Moss SJ, and Haydon PG (2007). mGluR5 stimulates gliotransmission in the nucleus accumbens. *Proc. Natl. Acad. Sci. USA* 104, 1995–2000. 10.1073/pnas.0609408104. [PubMed: 17259307]
- Devoto P, Flore G, Saba P, Fà M, and Gessa GL (2005). Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus. *BMC Neurosci.* 6, 31. 10.1186/1471-2202-6-31. [PubMed: 15865626]
- Dias R, Robbins TW, and Roberts AC (1996). Primate analogue of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. *Behav. Neurosci* 110, 872–886. 10.1037/0735-7044.110.5.872. [PubMed: 8918991]
- Ding F, O’Donnell J, Thrane AS, Zeppenfeld D, Kang H, Xie L, Wang F, and Nedergaard M (2013).  $\alpha_1$ -Adrenergic receptors mediate coordinated  $\text{Ca}^{2+}$  signaling of cortical astrocytes in awake, behaving mice. *Cell Calcium* 54, 387–394. 10.1016/j.ceca.2013.09.001. [PubMed: 24138901]
- Dos Santos Pereira JN, Tadjerpisheh S, Abed MA, Saadatmand AR, Weksler B, Romero IA, Couraud P-O, Brockmüller J, and Tzvetkov MV (2014). The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. *AAPS J.* 16, 1247–1258. 10.1208/s12248-014-9649-9. [PubMed: 25155823]
- Duan H, and Wang J (2010). Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. *J. Pharmacol. Exp. Ther* 335, 743–753. 10.1124/jpet.110.170142. [PubMed: 20858707]
- Dubbs A, Guevara J, and Yuste R (2016). Moco: fast motion correction for calcium imaging. *Front Neuroinformatics* 10, 6. 10.3389/fninf.2016.00006.
- Edelmann E, and Lessmann V (2018). Dopaminergic innervation and modulation of hippocampal networks. *Cell Tissue Res.* 373, 711–727. 10.1007/s00441-018-2800-7. [PubMed: 29470647]
- Feng J, Zhang C, Lischinsky JE, Jing M, Zhou J, Wang H, Zhang Y, Dong A, Wu Z, Wu H, et al. (2019). A genetically encoded fluorescent sensor for rapid and specific in vivo detection of norepinephrine. *Neuron* 102, 745–761.e8. 10.1016/j.neuron.2019.02.037. [PubMed: 30922875]
- Fischer T, Scheffler P, and Lohr C (2020). Dopamine-induced calcium signaling in olfactory bulb astrocytes. *Sci. Rep* 10, 631. 10.1038/s41598-020-57462-4. [PubMed: 31959788]
- Fritschy JM, and Grzanna R (1989). Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. *Neuroscience* 30, 181–197. 10.1016/0306-4522(89)90364-3. [PubMed: 2747911]

- Funahashi S, Bruce CJ, and Goldman-Rakic PS (1989). Mnemonic coding of visual space in the monkey's dorsolateral prefrontal cortex. *J. Neurophysiol* 61, 331–349. 10.1152/jn.1989.61.2.331. [PubMed: 2918358]
- Fuster JM, and Alexander GE (1971). Neuron activity related to short-term memory. *Science* 173, 652–654. 10.1126/science.173.3997.652. [PubMed: 4998337]
- Fuster JM, Bodner M, and Kroger JK (2000). Cross-modal and cross-temporal association in neurons of frontal cortex. *Nature* 405, 347–351. 10.1038/35012613. [PubMed: 10830963]
- Gao W-J, and Goldman-Rakic PS (2003). Selective modulation of excitatory and inhibitory microcircuits by dopamine. *Proc. Natl. Acad. Sci. USA* 700, 2836–2841. 10.1073/pnas.262796399.
- Gao W-J, Wang Y, and Goldman-Rakic PS (2003). Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. *J. Neurosci* 23, 1622–1630. 10.1523/jneurosci.23-05-01622.2003. [PubMed: 12629166]
- Garris PA, and Wightman RM (1994). Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. *J. Neurosci* 74, 442–450. 10.1523/jneurosci.14-01-00442.1994.
- George MS, Ketter TA, Parekh PI, Horwitz B, Herscovitch P, and Post RM (1995). Brain activity during transient sadness and happiness in healthy women. *Am. J. Psychiatry* 752, 341–351. 10.1176/ajp.152.3.341.
- Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, and Heintz N (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. *Nature* 425, 917–925. 10.1038/nature02033. [PubMed: 14586460]
- González S, Moreno-Delgado D, Moreno E, Pérez-Capote K, Franco R, Mallol J, Cortés A, Casadó V, Lluís C, Ortiz J, et al. (2012). Circadian-related heteromerization of adrenergic and dopamine D4 receptors modulates melatonin synthesis and release in the pineal gland. *PLoS Biol.* 10, e1001347. 10.1371/journal.pbio.1001347. [PubMed: 22723743]
- Gordon GRJ, Baimoukhametova DV, Hewitt SA, Rajapaksha WRA, Fisher TE, and Bains JS (2005). Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. *Nat. Neurosci* 8, 1078–1086. 10.1038/nn1498. [PubMed: 15995701]
- Gresch PJ, Sved AF, Zigmond MJ, and Finlay JM (1994). Stress-induced sensitization of dopamine and norepinephrine efflux in medial prefrontal cortex of the rat. *J. Neurochem* 63, 575–583. 10.1046/j.1471-4159.1994.63020575.x. [PubMed: 8035182]
- Guiard BP, El Mansari M, and Blier P (2008). Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. *Mol. Pharmacol* 74, 1463–1475. 10.1124/mol.108.048033. [PubMed: 18703671]
- Harada K, Ito M, Wang X, Tanaka M, Wongso D, Konno A, Hirai H, Hirase H, Tsuboi T, and Kitaguchi T (2017). Red fluorescent protein-based cAMP indicator applicable to optogenetics and in vivo imaging. *Sci. Rep* 7, 7351. 10.1038/s41598-017-07820-6. [PubMed: 28779099]
- Hariri AR, Mattay VS, Tessitore A, Fera F, and Weinberger DR (2003). Neocortical modulation of the amygdala response to fearful stimuli. *Biol. Psychiatry* 53, 494–501. 10.1016/s0006-3223(02)01786-9. [PubMed: 12644354]
- Huang Y-Y, Simpson E, Kellendonk C, and Kandel ER (2004). Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors. *Proc. Natl. Acad. Sci. USA* 101, 3236–3241. 10.1073/pnas.0308280101. [PubMed: 14981263]
- Hurst JL, and West RS (2010). Taming anxiety in laboratory mice. *Nat. Methods* 7, 825–826. 10.1038/nmeth.1500. [PubMed: 20835246]
- Inagaki HK, Fontolan L, Romani S, and Svoboda K (2019). Discrete attractor dynamics underlies persistent activity in the frontal cortex. *Nature* 566, 212–217. 10.1038/s41586-019-0919-7. [PubMed: 30728503]
- Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, Rasmussen SGF, Sunahara RK, El-Samad H, Huang B, and von Zastrow M (2013). Conformational biosensors reveal GPCR signal-ling from endosomes. *Nature* 495, 534–538. 10.1038/nature12000. [PubMed: 23515162]

- Jennings A, Tyurikova O, Bard L, Zheng K, Semyanov A, Henneberger C, and Rusakov DA (2017). Dopamine elevates and lowers astroglial Ca<sup>2+</sup> through distinct pathways depending on local synaptic circuitry. *Glia* 65, 447–459. 10.1002/glia.23103. [PubMed: 27896839]
- John CS, Smith KL, Van't Veer A, Gompf HS, Carlezon WA, Cohen M, Öngür D, and Bechtholt-Gompf AJ (2012). Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. *Neuropsychopharmacology* 37, 2467–2475. 10.1038/npp.2012.105. [PubMed: 22739467]
- Kesner RP, Hunt ME, Williams JM, and Long JM (1996). Prefrontal cortex and working memory for spatial response, spatial location, and visual object information in the rat. *Cereb. Cortex* 6, 311–318. 10.1093/cercor/6.2.311. [PubMed: 8670659]
- Khakh BS, and Sofroniew MV (2015). Diversity of astrocyte functions and phenotypes in neural circuits. *Nat. Neurosci* 18, 942–952. 10.1038/nn.4043. [PubMed: 26108722]
- Kim H, Somerville LH, Johnstone T, Alexander AL, and Whalen PJ (2003). Inverse amygdala and medial prefrontal cortex responses to surprised faces. *Neuroreport* 14, 2317–2322. 10.1097/00001756-200312190-00006. [PubMed: 14663183]
- Kirshner N (1957). Pathway of noradrenaline formation from DOPA. *J. Biol. Chem* 226, 821–825. 10.1016/s0021-9258(18)70865-x. [PubMed: 13438868]
- Kofuji P, and Araque A (2021). G-Protein-Coupled receptors in astrocyte-neuron communication. *Neuroscience* 456, 71–84. 10.1016/j.neuroscience.2020.03.025. [PubMed: 32224231]
- Kotowski SJ, Hopf FW, Seif T, Bonci A, and von Zastrow M (2011). Endocytosis promotes rapid dopaminergic signaling. *Neuron* 71, 278–290. 10.1016/j.neuron.2011.05.036. [PubMed: 21791287]
- Kröner S, Krimer LS, Lewis DA, and Barrionuevo G (2007). Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons. *Cereb. Cortex* 17, 1020–1032. 10.1093/cercor/bhl012. [PubMed: 16772311]
- Lalo U, Palygin O, Rasooli-Nejad S, Andrew J, Haydon PG, and Pankratov Y (2014). Exocytosis of ATP from astrocytes modulates phasic and tonic inhibition in the neocortex. *PLoS Biol.* 12, e1001747. 10.1371/journal.pbio.1001747. [PubMed: 24409095]
- Lammel S, Hetzel A, Hackel O, Jones I, Liss B, and Roeper J (2008). Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. *Neuron* 57, 760–773. 10.1016/j.neuron.2008.01.022. [PubMed: 18341995]
- Lammel S, Lim BK, Ran C, Huang KW, Betley MJ, Tye KM, Deisseroth K, and Malenka RC (2012). Input-specific control of reward and aversion in the ventral tegmental area. *Nature* 491, 212–217. 10.1038/nature11527. [PubMed: 23064228]
- Lanjakornsiripan D, Pior B-J, Kawaguchi D, Furutachi S, Tahara T, Katsuyama Y, Suzuki Y, Fukazawa Y, and Gotoh Y (2018). Layer-specific morphological and molecular differences in neocortical astrocytes and their dependence on neuronal layers. *Nat. Commun* 9, 1623. 10.1038/s41467-018-03940-3. [PubMed: 29691400]
- Lee Y, Son H, Kim G, Kim S, Lee DH, Roh GS, Kang SS, Cho GJ, Choi WS, and Kim HJ (2013). Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice. *J. Psychiatry Neurosci* 38, 183–191. 10.1503/jpn.120024. [PubMed: 23031251]
- Lee SJ, Lodder B, Chen Y, Patriarchi T, Tian L, and Sabatini BL (2021). Cell-type-specific asynchronous modulation of PKA by dopamine in learning. *Nature* 590, 451–456. 10.1038/s41586-020-03050-5. [PubMed: 33361810]
- Levene MJ, Dombeck DA, Kasischke KA, Molloy RP, and Webb WW (2004). In vivo multiphoton microscopy of deep brain tissue. *J. Neurophysiol* 91, 1908–1912. 10.1152/jn.01007.2003. [PubMed: 14668300]
- Li X, Zima AV, Sheikh F, Blatter LA, and Chen J (2005). Endothelin-1-induced arrhythmogenic Ca<sup>2+</sup> signaling is abolished in atrial myocytes of inositol-1, 4, 5-trisphosphate(IP<sub>3</sub>)-receptor type 2-deficient mice. *Circ. Res* 96, 1274–1281. 10.1161/01.res.0000172556.05576.4c. [PubMed: 15933266]
- Lima A, Sardinha VM, Oliveira AF, Reis M, Mota C, Silva MA, Marques F, Cerqueira JJ, Pinto L, Sousa N, and Oliveira JF (2014). Astrocyte pathology in the prefrontal cortex impairs the cognitive function of rats. *Mol. Psychiatry* 19, 834–841. 10.1038/mp.2013.182. [PubMed: 24419043]

- Lohani S, Martig AK, Deisseroth K, Witten IB, and Moghaddam B (2019). Dopamine modulation of prefrontal cortex activity is manifold and operates at multiple temporal and spatial scales. *Cell Rep.* 27,99–114.e6. 10.1016/j.celrep.2019.03.012. [PubMed: 30943418]
- Marek GJ, and Aghajanian GK (1999). 5-HT<sub>2A</sub> receptor or  $\alpha$ 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. *Eur. J. Pharmacol* 367, 197–206. 10.1016/s0014-2999(98)00945-5. [PubMed: 10078993]
- Martin-Fernandez M, Jamison S, Robin LM, Zhao Z, Martin ED, Aguilar J, Benneyworth MA, Marsicano G, and Araque A (2017). Synapse-specific astrocyte gating of amygdala-related behavior. *Nat. Neurosci* 20, 1540–1548. 10.1038/nn.4649. [PubMed: 28945222]
- Matsuda Y, Marzo A, and Otani S (2006). The presence of background dopamine signal converts long-term synaptic depression to potentiation in rat prefrontal cortex. *J. Neurosci* 26, 4803–4810. 10.1523/jneurosci.5312-05.2006. [PubMed: 16672653]
- Mederos S, Sanchez-Puelles C, Esparza J, Valero M, Ponomarenko A, and Perea G (2021). GABAergic signaling to astrocytes in the prefrontal cortex sustains goal-directed behaviors. *Nat. Neurosci* 24, 82–92. 10.1038/s41593-020-00752-x. [PubMed: 33288910]
- Milad MR, and Quirk GJ (2002). Neurons in medial prefrontal cortex signal memory for fear extinction. *Nature* 420, 70–74. 10.1038/nature01138. [PubMed: 12422216]
- Mitrano DA, Pare JF, Smith Y, and Weinschenker D (2014). D1-dopamine and  $\alpha$ 1-adrenergic receptors co-localize in dendrites of the rat prefrontal cortex. *Neuroscience* 258, 90–100. 10.1016/j.neuroscience.2013.11.002. [PubMed: 24231738]
- Morón JA, Brockington A, Wise RA, Rocha BA, and Hope BT (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. *J. Neurosci* 22, 389–395. 10.1523/jneurosci.22-02-00389.2002. [PubMed: 11784783]
- Muntean BS, Zucca S, MacMullen CM, Dao MT, Johnston C, Iwamoto H, Blakely RD, Davis RL, and Martemyanov KA (2018). Interrogating the spatiotemporal landscape of neuromodulatory GPCR signaling by real-time imaging of cAMP in intact neurons and circuits. *Cell Rep.* 22, 255–268. 10.1016/j.celrep.2017.12.022. [PubMed: 29298426]
- Murphy-Royal C, Johnston AD, Boyce AKJ, Diaz-Castro B, Institoris A, Peringod G, Zhang O, Stout RF, Spray DC, Thompson RJ, et al. (2020). Stress gates an astrocytic energy reservoir to impair synaptic plasticity. *Nat. Commun* 11, 2014. 10.1038/s41467-020-15778-9. [PubMed: 32332733]
- Nagai J, Rajbhandari AK, Gangwani MR, Hachisuka A, Coppola G, Masmanidis SC, Faselow MS, and Khakh BS (2019). Hyperactivity with disrupted attention by activation of an astrocyte synaptogenic cue. *Cell* 177, 1280–1292.e20. 10.1016/j.cell.2019.03.019. [PubMed: 31031006]
- Nicola SM, and Malenka RC (1997). Dopamine depresses excitatory and inhibitory synaptic transmission by distinct mechanisms in the nucleus accumbens. *J. Neurosci* 17, 5697–5710. 10.1523/jneurosci.17-15-05697.1997. [PubMed: 9221769]
- Nomura S, Bouhadana M, Morel C, Faure P, Cauli B, Lambolez B, and Hepp R (2014). Noradrenalin and dopamine receptors both control cAMP-PKA signaling throughout the cerebral cortex. *Front. Cell. Neurosci* 8, 247. 10.3389/fncel.2014.00247. [PubMed: 25191229]
- Oe Y, Wang X, Patriarchi T, Konno A, Ozawa K, Yahagi K, Hirai H, Tsuboi T, Kitaguchi T, Tian L, et al. (2020). Distinct temporal integration of noradrenaline signaling by astrocytic second messengers during vigilance. *Nat. Commun* 11, 471. 10.1038/s41467-020-14378-x. [PubMed: 31980655]
- Özkan M, Johnson NW, Sehrlir US, Woodhall GL, and Stanford IM (2017). Dopamine acting at D1-like, D2-like and  $\alpha$ 1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex. *PLoS One* 12, e0181633. 10.1371/journal.pone.0181633. [PubMed: 28732063]
- Panatier A, Vallée J, Haber M, Murai KK, Lacaille J-C, and Robitaille R (2011). Astrocytes are endogenous regulators of basal transmission at central synapses. *Cell* 146, 785–798. 10.1016/j.cell.2011.07.022. [PubMed: 21855979]
- Pankratov Y, and Lalo U (2015). Role for astroglial  $\alpha$ 1-adrenoreceptors in gliotransmission and control of synaptic plasticity in the neocortex. *Front. Cell. Neurosci* 9, 230. 10.3389/fncel.2015.00230. [PubMed: 26136663]




- Park JC, Bae JW, Kim J, and Jung MW (2019). Dynamically changing neuronal activity supporting working memory for predictable and unpredictable durations. *Sci. Rep* 9, 15512. 10.1038/s41598-019-52017-8. [PubMed: 31664169]
- Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul J-Y, Takano H, Moss SJ, McCarthy K, and Haydon PG (2005). Astrocytic purinergic signaling coordinates synaptic networks. *Science* 310, 113–116. 10.1126/science.1116916. [PubMed: 16210541]
- Patriarchi T, Cho JR, Merten K, Howe MW, Marley A, Xiong W-H, Folk RW, Broussard GJ, Liang R, Jang MJ, et al. (2018). Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors. *Science* 360, eaat4422. 10.1126/science.aat4422. [PubMed: 29853555]
- Paukert M, Agarwal A, Cha J, Doze VA, Kang JU, and Bergles DE (2014). Norepinephrine controls astroglial responsiveness to local circuit activity. *Neuron* 82, 1263–1270. 10.1016/j.neuron.2014.04.038. [PubMed: 24945771]
- Perea G, and Araque A (2007). Astrocytes potentiate transmitter release at single hippocampal synapses. *Science* 317, 1083–1086. 10.1126/science.1144640. [PubMed: 17717185]
- Petravicz J, Fiacco TA, and McCarthy KD (2008). Loss of IP3 receptor-dependent Ca<sup>2+</sup> increases in hippocampal astrocytes does not affect baseline CA1 pyramidal neuron synaptic activity. *J. Neurosci* 28, 4967–4973. 10.1523/jneurosci.5572-07.2008. [PubMed: 18463250]
- Petrelli F, Dallérac G, Pucci L, Calì C, Zehnder T, Sultan S, Lecca S, Chicca A, Ivanov A, Asensio CS, et al. (2020). Dysfunction of homeostatic control of dopamine by astrocytes in the developing prefrontal cortex leads to cognitive impairments. *Mol. Psychiatry* 25, 732–749. 10.1038/s41380-018-0226-y. [PubMed: 30127471]
- Porter JT, and McCarthy KD (1997). Astrocytic neurotransmitter receptors in situ and in vivo. *Prog. Neurobiol* 51, 439–455. 10.1016/s0301-0082(96)00068-8. [PubMed: 9106901]
- Poskanzer KE, and Yuste R (2016). Astrocytes regulate cortical state switching in vivo. *Proc. Natl. Acad. Sci. USA* 113, E2675–E2684. 10.1073/pnas.1520759113. [PubMed: 27122314]
- Pougnat J-T, Toulme E, Martinez A, Choquet D, Hosi E, and Boué-Grabot E (2014). ATP P2X receptors downregulate AMPA receptor trafficking and postsynaptic efficacy in hippocampal neurons. *Neuron* 83, 417–430. 10.1016/j.neuron.2014.06.005. [PubMed: 25033184]
- Proudman RGW, and Baker JG (2021). The selectivity of  $\alpha$ -adrenoceptor agonists for the human  $\alpha$ 1A,  $\alpha$ 1B, and  $\alpha$ 1D-adrenoceptors. *Pharmacol. Res. Perspect* 9, e00799. 10.1002/prp2.799. [PubMed: 34355529]
- Ragozzino ME, Detrick S, and Kesner RP (1999). Involvement of the prelimbic-infralimbic areas of the rodent prefrontal cortex in behavioral flexibility for place and response learning. *J. Neurosci* 19, 4585–4594. 10.1523/jneurosci.19-11-04585.1999. [PubMed: 10341256]
- Rebois RV, Maki K, Meeks JA, Fishman PH, Hébert TE, and Northup JK (2012). D2-like dopamine and  $\beta$ -adrenergic receptors form a signaling complex that integrates Gs- and Gi-mediated regulation of adenylyl cyclase. *Cell. Signal* 24, 2051–2060. 10.1016/j.cellsig.2012.06.011. [PubMed: 22759790]
- Rosenkranz JA, and Grace AA (2001). Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats. *J. Neurosci* 21, 4090–4103. 10.1523/jneurosci.21-11-04090.2001. [PubMed: 11356897]
- Sardinha VM, Guerra-Gomes S, Caetano I, Tavares G, Martins M, Reis JS, Correia JS, Teixeira-Castro A, Pinto L, Sousa N, and Oliveira JF (2017). Astrocytic signaling supports hippocampal-prefrontal theta synchronization and cognitive function. *Glia* 65, 1944–1960. 10.1002/glia.23205. [PubMed: 28885722]
- Seamans JK, Gorelova N, Durstewitz D, and Yang CR (2001). Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. *J. Neurosci* 27, 3628–3638. 10.1523/jneurosci.21-10-03628.2001.
- Sesack SR, Hawrylak VA, Matus C, Guido MA, and Levey AI (1998). Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. *J. Neurosci* 78, 2697–2708. 10.1523/jneurosci.18-07-02697.1998.

- Shigetomi E, Kracun S, Sofroniew MV, and Khakh BS (2010). A genetically targeted optical sensor to monitor calcium signals in astrocyte processes. *Nat. Neurosci* 13, 759–766. 10.1038/nn.2557. [PubMed: 20495558]
- Shuen JA, Chen M, Gloss B, and Calakos N (2008). *Drd1a*-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. *J. Neurosci* 28, 2681–2685. 10.1523/jneurosci.5492-07.2008. [PubMed: 18337395]
- Simard S, Coppola G, Rudyk CA, Hayley S, McQuaid RJ, and Salmaso N (2018). Profiling changes in cortical astroglial cells following chronic stress. *Neuropsychopharmacology* 43, 1961–1971. 10.1038/s41386-018-0105-x. [PubMed: 29907879]
- Slezak M, Kandler S, Van Veldhoven PP, Van den Haute C, Bonin V, and Holt MG (2019). Distinct mechanisms for visual and motor-related astrocyte responses in mouse visual cortex. *Curr. Biol* 29, 3120–3127.e5. 10.1016/j.cub.2019.07.078. [PubMed: 31495587]
- Spaak E, Watanabe K, Funahashi S, and Stokes MG (2017). Stable and dynamic coding for working memory in primate prefrontal cortex. *J. Neurosci* 37, 6503–6516. 10.1523/jneurosci.3364-16.2017. [PubMed: 28559375]
- Srinivasan R, Lu T-Y, Chai H, Xu J, Huang BS, Golshani P, Coppola G, and Khakh BS (2016). New transgenic mouse lines for selectively targeting astrocytes and studying calcium signals in astrocyte processes in situ and in vivo. *Neuron* 92, 1181–1195. 10.1016/j.neuron.2016.11.030. [PubMed: 27939582]
- Stanford SC, and Heal DJ (2019). Catecholamines: knowledge and understanding in the 1960s, now, and in the future. *Brain Neurosci. Adv* 3. 10.1177/2398212818810682.
- Steinberg SF, and Bilezikian JP (1982). Identification and characterization of alpha1 adrenergic receptors in rat myocardium with a new iodinated radioligand, [125I]IBE 2254. *J. Mol. Cell. Cardiol* 14, 601–610. 10.1016/0022-2828(82)90146-8. [PubMed: 6130159]
- Thierry AM, Tassin JP, Blanc G, and Glowinski J (1976). Selective activation of the mesocortical DA system by stress. *Nature* 263, 242–244. 10.1038/263242a0. [PubMed: 958479]
- Tsai H-H, Li H, Fuentealba LC, Molofsky AV, Taveira-Marques R, Zhuang H, Tenney A, Murnen AT, Fancy SPJ, Merkle F, et al. (2012). Regional astrocyte allocation regulates CNS synaptogenesis and repair. *Science* 337, 358–362. 10.1126/science.1222381. [PubMed: 22745251]
- Vander Weele CM, Siciliano CA, Matthews GA, Namburi P, Izadmehr EM, Espinel IC, Nieh EH, Schut EHS, Padilla-Coreano N, Burgos-Robles A, et al. (2018). Dopamine enhances signal-to-noise ratio in cortical-brainstem encoding of aversive stimuli. *Nature* 563, 397–401. 10.1038/s41586-018-0682-1. [PubMed: 30405240]
- Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, and Arnsten AFT (2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. *Nat. Neurosci* 10, 376–384. 10.1038/nn1846. [PubMed: 17277774]
- Wang Y, DelRosso NV, Vaidyanathan TV, Cahill MK, Reitman ME, Pittolo S, Mi X, Yu G, and Poskanzer KE (2019). Accurate quantification of astrocyte and neurotransmitter fluorescence dynamics for single-cell and population-level physiology. *Nat. Neurosci* 22, 1936–1944. 10.1038/s41593-019-0492-2. [PubMed: 31570865]
- Wang Q, Kong Y, Wu D-Y, Liu J-H, Jie W, You Q-L, Huang L, Hu J, Chu H-D, Gao F, et al. (2021). Impaired calcium signaling in astrocytes modulates autism spectrum disorder-like behaviors in mice. *Nat. Commun* 12, 3321. 10.1038/s41467-021-23843-0. [PubMed: 34059669]
- Wu Z, He K, Chen Y, Li H, Pan S, Li B, Liu T, Wang H, Du J, Jing M, et al. (2021). An ultrasensitive GRAB sensor for detecting extracellular ATP in vitro and in vivo. Preprint at bioRxiv. 10.1101/2021.02.24.432680.
- Xin W, Schuebel KE, Jair K-W, Cimbro R, De Biase LM, Goldman D, and Bonci A (2019). Ventral midbrain astrocytes display unique physiological features and sensitivity to dopamine D2 receptor signaling. *Neuropsychopharmacology* 44, 344–355. 10.1038/s41386-018-0151-4. [PubMed: 30054584]
- Yang J, Vitery MDC, Chen J, Osei-Owusu J, Chu J, and Qiu Z (2019). Glutamate-releasing SWELL1 channel in astrocytes modulates synaptic transmission and promotes brain damage in stroke. *Neuron* 102, 813–827.e6. 10.1016/j.neuron.2019.03.029. [PubMed: 30982627]

- Yapo C, Nair AG, Clement L, Castro LR, Hellgren Kotaleski J, and Vincent P (2017). Detection of phasic dopamine by D1 and D2 striatal medium spiny neurons. *J. Physiol. (Lond.)* 595, 7451–7475. 10.1113/jp274475. [PubMed: 28782235]
- Zhang J.m., Wang H.k., Ye C.q., Ge W, Chen Y, Jiang Z.l., Wu C.p., Poo M.m., and Duan S (2003). ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. *Neuron* 40, 971–982. 10.1016/s0896-6273(03)00717-7. [PubMed: 14659095]
- Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J. Neurosci* 34, 11929–11947. 10.1523/jneurosci.1860-14.2014. [PubMed: 25186741]
- Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, and Barlow DP (2001). Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in *Orct3/Slc22a3*-deficient mice. *Mol. Cell Biol* 21, 4188–4196. 10.1128/mcb.21.13.4188-4196.2001. [PubMed: 11390648]

### Highlights

- Prefrontal and visual cortex astrocytes display different  $\text{Ca}^{2+}$  signatures *in vivo*
- Dopamine recruits PFC astrocyte  $\text{Ca}^{2+}$ —but not cAMP—within seconds
- Dopamine induces ATP release at PFC astrocyte territories
- $\alpha 1$ -Adrenergic receptors are involved in the response of PFC astrocytes to dopamine



**Figure 1. PFC astrocytes exhibit region-specific  $\text{Ca}^{2+}$  activity**

(A) Schematic for *in vivo* head-fixed 2P imaging of astrocyte  $\text{Ca}^{2+}$  in the PFC (via GRIN lens) or V1 (cranial window).


(B) Representative frames of astrocytic GCaMP6f fluorescence in PFC (top) or V1 (bottom), relative to  $\text{Ca}^{2+}$  event onset.

(C) Two examples of large AQUA-detected  $\text{Ca}^{2+}$  events each in PFC (red, top) and V1 (green, bottom). Fields of view =  $300 \times 300 \mu\text{m}^2$ . To the right of each image is the corresponding time course of all detected events within 10 s, with the onset time of the largest event at  $t = 0$  and solid line indicating frame displayed at left. Events  $< 1,000 \mu\text{m}^2$  in gray.

(D–H) Large astrocyte  $\text{Ca}^{2+}$ -event features vary between brain regions. (D–F) Events occur at similar rates in the PFC and V1 (D) but in the PFC are (E) smaller and (F) longer than in V1. (G and H) PFC events (G) co-occur with other events less than in V1 but (H) tend to repeat more at the same location. All bins/events (colored dots), 5<sup>th</sup>–95<sup>th</sup> percentile distribution (violins), and mean  $\pm$  SEM (black dots and error bars). Event rate ( $\text{min}^{-1}$ ):  $0.38 \pm 0.05$  (PFC) and  $0.42 \pm 0.08$  (V1); area ( $\mu\text{m}^2$ ):  $2,422 \pm 190$  (PFC) and  $6,639 \pm 1,346$

(V1); duration (s):  $12.6 \pm 1.1$  (PFC) and  $9.4 \pm 0.5$  (V1); temporal co-occurrence:  $1.06 \pm 0.03$  (PFC) and  $1.87 \pm 0.13$  (V1); spatial co-occurrence:  $4.7 \pm 0.5$  (PFC) and  $2.9 \pm 0.3$  (V1). Wilcoxon rank-sum test; \* $p < 0.05$ ;  $p = 0.629$  (frequency),  $p = 0.012$  (area),  $p = 0.012$  (duration),  $p < 10^{-4}$  (co-occurring),  $p = 0.034$  (co-localized). PFC:  $n = 180$  60 s bins, 68 events, 4 mice; V1:  $n = 130$  60 s bins, 55 events, 3 mice.


(I–M) Locomotion does not induce population-wide astrocyte  $\text{Ca}^{2+}$  in PFC. (I) Example time course of normalized astrocyte  $\text{Ca}^{2+}$  (colored trace, top) and corresponding mouse speed (black, bottom). (J–K) Astrocyte  $\text{Ca}^{2+}$  traces aligned to locomotion onset ( $t = 0$ ), shown as heatmaps for all recordings (J), average traces  $\pm$  SEM (K, left), and binned distribution of maximum  $\text{Ca}^{2+}$  change (K, right). In (K), line above traces indicates significant change from average  $\text{Ca}^{2+}$  at  $t < 0$ . Shuffle test, 10,000 pairwise shuffles;  $p < 0.01$ , Bonferroni correction for multiple comparisons. PFC:  $n = 84$  bouts, 4 mice; V1:  $n = 77$  bouts, 3 mice. (L–M) Animal speed aligned to onset of astrocyte  $\text{Ca}^{2+}$  events ( $t = 0$ ), shown as heatmap for all recordings (L), average traces  $\pm$  SEM (M, left), and binned distribution of maximal speed (M, right). In (M), line above traces indicates significant increase above average speed for entire window. Shuffle test, 10,000 pairwise shuffles;  $p < 0.01$ , Bonferroni correction for multiple comparisons. PFC:  $n = 424$  events, 4 mice; V1:  $n = 1,501$  events, 3 mice.



**Figure 2. D<sub>1</sub> and D<sub>2</sub> are expressed by PFC astrocytes but do not recruit G<sub>s</sub>/G<sub>i</sub> pathways**  
 (A) Transgenic crosses to identify co-expression of D<sub>1</sub> (left column, top) or D<sub>2</sub> (right column, top) with astrocytic Aldh111 (middle row). Whole-brain coronal sections containing PFC.  
 (B) Example of marker colocalization in PFC of *Drd1*-tdTomato × *Aldh111*-GFP mouse. Arrowheads indicate astrocytes co-expressing D<sub>1</sub> (magenta) and Aldh111 (green). Boundaries between cortical layers indicated by dashed lines.  
 (C–D) Percentage of (C) Aldh111<sup>+</sup> astrocytes expressing D<sub>1</sub> (Drd1<sup>+</sup>, magenta) and D<sub>2</sub> (Drd2<sup>+</sup>, green) and of (D) Drd1<sup>+</sup> (magenta) and Drd2<sup>+</sup> (green) cells that co-express Aldh111 in PFC. Mean ± SEM; n = 3 sections/mouse, 3 (D<sub>1</sub>) and 2 (D<sub>2</sub>) mice.  
 (E) Schematic for 2P cAMP imaging in acute PFC slices. Micrographs show Pink Flamindo expression in entire field of view (top) and 3 cells with astrocyte morphology (bottom).  
 (F) DR agonists (colors) do not mobilize whole-cell cAMP in PFC astrocytes. AC activator forskolin (black) in the same slices confirms Pink Flamindo activity. Boxes on traces indicate 20-s windows used for quantification in (G). Traces shown as slice averages ± SEM of whole-cell changes in Pink Flamindo intensity (dF/F); n = 110–180 cells, 7–8 slices, 7–8 mice.  
 (G) Quantification of (F) at time points indicated by small boxes, shown as boxplots indicating mean and 10<sup>th</sup>–90<sup>th</sup> percentile, and error bars indicating minima and maxima.

Slice mean  $\pm$  SEM (control, +drug, +forskolin):  $-0.003 \pm 0.004$ ,  $0.02 \pm 0.01$ ,  $0.24 \pm 0.03$  (DA);  $0.003 \pm 0.002$ ,  $0.006 \pm 0.007$ ,  $0.13 \pm 0.01$  (D1);  $0.003 \pm 0.002$ ,  $0.016 \pm 0.007$ ,  $0.18 \pm 0.03$  (D2). Friedman test after Levene test; n.s.,  $p > 0.05$ ,  $**p < 0.01$ ; not shown on graph are the comparison between drug and forskolin ( $p < 0.05$  for all agonists) and comparisons within conditions (controls, drugs, or forskolins; one-way ANOVA or Kruskal-Wallis after Levene test, all  $p > 0.05$ );  $n = 110\text{--}180$  cells, 7–8 slices, 7–8 mice.





**Figure 3. DA mobilizes astrocytic  $\text{Ca}^{2+}$  in PFC slices via cell-surface ARs**

(A) Schematic for 2P astrocytic  $\text{Ca}^{2+}$  imaging in acute slices.

(B) Representative micrograph of GCaMP6f expression in imaged PFC area. Note y axis measurements of distance to slice midline, used for spatial plots in (D).

(C) All AQUA-detected  $\text{Ca}^{2+}$  events 0–60 s before (left) and 90–150 s after DA bath application (right) from same slice as in (B). Colors represent individual events.

(D) Time course of all  $\text{Ca}^{2+}$  events detected over entire recording of slice in (B) and (C) and event onset rate (top) relative to 10  $\mu\text{M}$  DA ( $t = 0$ ). Shaded areas represent approximate event size and mean event y position over time.

(E) Astrocytic  $\text{Ca}^{2+}$ -event rate (count/5 s) in PFC slices after treatment with indicated drugs. Treatment with both D1 and D2 agonists SKF38393 and quinpirole (yellow) did not induce increased  $\text{Ca}^{2+}$  events as DA did (magenta). Blocking both D1R and D2R with antagonists SCH23390 and sulpiride during DA application (blue) failed to occlude astrocyte activation by DA, whereas the effect of DA alone was reduced in  $\text{IP}_3\text{R}2^{-/-}$  mice (gray). Non-selective  $\alpha$ - and  $\beta$ -AR antagonists phentolamine and propranolol (green) reduced  $\text{Ca}^{2+}$  responses to DA. Slices (transparent dots) and corresponding mean  $\pm$  SEM (solid dot and error bar):  $48.0 \pm 10.2$  (DA);  $8.0 \pm 2.5$  (D1/D2 agonist);  $23.6 \pm 4.6$  (DR antagonist);  $9.9 \pm 3.3$  ( $\text{IP}_3\text{R}2^{-/-}$ );  $9.3 \pm 2.5$  (AR antagonist). Kruskal-Wallis test after Levene test; \* $p < 0.05$  compared with


DA condition; all other comparisons between conditions (not shown),  $p > 0.79$ ;  $n = 5-8$  slices, 4–8 mice.

(F) Example of tissue-wide expression of GRAB<sub>NE</sub> in acute slice.

(G) DA is not metabolized to NE in PFC slices, as indicated by GRAB<sub>NE</sub>. Left: trace means  $\pm$  SEM relative to either DA or NE addition at  $t = 0$ . Right: slices (dots) and mean  $\pm$  SEM (dot with error bar) of 20 s GRAB<sub>NE</sub> dF/F averages at baseline (black), or 6 min after 10  $\mu$ M DA (magenta) and 10  $\mu$ M NE (gray):  $-0.002 \pm 0.003$  (baseline);  $0.055 \pm 0.012$  (DA);  $1.490 \pm 0.165$  (NE). Kruskal-Wallis test after Levene test; \*\*\* $p < 0.001$  relative to baseline;  $n = 6$  slices, 4 mice.

(H) Example slice from OCT3<sup>-/-</sup> mice with deficient DA uptake, loaded with the Ca<sup>2+</sup> indicator Fluo-4.

(I) Somatic Ca<sup>2+</sup> signals in response to bath-applied DA are present in PFC astrocytes in the OCT3<sup>-/-</sup> background. Left: mean trace (black) and slice average traces of active cells (gray) relative to 10  $\mu$ M DA addition at  $t = 0$ . Right: slice averages (lines) and corresponding mean  $\pm$  SEM (dots and error bars) of Fluo-4 dF/F extracted from traces on left at either 100 s before (basal) or after DA (+DA):  $-0.04 \pm 0.02$  (baseline);  $0.22 \pm 0.08$  (+DA). Paired t test after Anderson-Darling test; \* $p < 0.05$ ;  $n = 138$  active cells, 6 slices, 3 mice.



**Figure 4. Photo-uncaging releases physiological concentrations of DA and activates astrocyte territories in seconds**

(A) Schematic for fast release of DA in PFC slices using RuBi-DA uncaging with a blue LED, combined with simultaneous 2P imaging of DA (dLight1.2) or astrocytic  $\text{Ca}^{2+}$  (GCaMP6f).

(B) Representative dLight expression in an acute PFC slice.

(C) dLight dose response to DA in PFC slices and Hill equation fit function (solid line).

Dotted lines indicate DA concentration at dLight half-maximum. Slices mean  $\pm$  SEM (dots and error bars);  $n = 4$  slices, 2 mice.

(D) dLight fluorescence (dF/F) increases after LED stimulation ( $3 \times 100$  ms pulses, blue line) in presence of RuBi-DA (magenta) but not in control without RuBi-DA in bath (gray). Trace mean  $\pm$  SEM;  $n = 6-7$  slices, 3 mice.

(E) Estimated DA concentration post-uncaging was  $2 \mu\text{M}$ , extrapolated from fit function in (C) using data from (D) obtained as 30-s dF/F means after LED stimulus. All slices (transparent dots) and corresponding mean  $\pm$  SEM (solid dot and error bar):  $0.41 \pm 0.03$  (control),  $2.0 \pm 0.2$  (RuBi-DA)  $\mu\text{M}$ . Two-sample t test,  $***p < 10^{-6}$ ;  $n = 6-7$  slices, 3 mice.

(F) Representative PFC slice for 2P imaging of astrocytic GCaMP (top) with corresponding astrocyte territories (bottom).

(G) Raster plots of AQuA-detected  $\text{Ca}^{2+}$  events (top) show time course of events within cells from slice in (F), plotted relative to LED (blue lines,  $t = 0$ ) before (left, control) and after bathing on RuBi-DA (right). Colors indicate co-occurring event number/cell. Bottom graphs: cumulative event counts across cells.

(H)  $\text{Ca}^{2+}$  activity increases for majority of cells in 60 s after uncaging (70%), while cells are largely inactive (no events throughout recording; 91%) in the control condition. Percentage


of cells decreasing or maintaining their activity after uncaging is similar between conditions. Mean  $\pm$  SEM; n = 540–1,118 cells, 5–11 slices, 5–8 mice. Percentage of cells (control, RuBi-DA): 91  $\pm$  2, 30  $\pm$  7 (inactive); 4  $\pm$  1, 62  $\pm$  8 (increase); 4  $\pm$  1, 4  $\pm$  1 (decrease); 0  $\pm$  0, 4  $\pm$  1 (no change).

(I) Ca<sup>2+</sup> event features (number, area, duration) in active cells in (H) increase significantly in the 60 s after uncaging (blue boxes) with RuBi-DA (magenta) but not without (control, black). Slice averages of active cells (gray lines) and mean  $\pm$  SEM (dots and error bars). Event number (pre- and post-uncaging): 0.06  $\pm$  0.02, 0.07  $\pm$  0.01 (control); 0.17  $\pm$  0.03, 1.22  $\pm$  0.16 (RuBi-DA). Event area ( $\mu\text{m}^2$ ): 25  $\pm$  7, 23  $\pm$  3 (control); 20  $\pm$  5, 443  $\pm$  104 (RuBi-DA). Event duration (s): 3.0  $\pm$  0.7, 2.7  $\pm$  0.2 (control); 1.9  $\pm$  0.8, 11.3  $\pm$  1.5 (RuBi-DA). Paired t test comparing pre- with post-uncaging; \*\*p < 0.01; \*\*\*p < 0.001. Control: n = 47/540 active/total cells, 5 slices and mice. RuBi-DA: n = 784/1,118 cells, 11 slices, 8 mice.

(J) Example of Ca<sup>2+</sup> activation within cells 5 s after uncaging pulse, either in control (left) or with RuBi-DA (right). Maps are zoomed in from (F). Gray, cell areas; magenta, active pixels.

(K) Time course of percentage of cell area active relative to uncaging (blue lines) in absence and presence of RuBi-DA. Cells, slices, and overall mean (gray, thin, and thick colored lines, respectively). Control: n = 47/540 cells, 5 slices and mice. RuBi-DA: n = 784/1,118 cells, 11 slices, 8 mice.

(L) Response to DA (magenta) occurs within seconds (left, delay), lasts <20 s (middle, peak full-width half-maximum), and recruits a range of areas within individual astrocytes (right, percentage of cell surface). In controls (black), few cells were active post-uncaging, with short activity (<9 s) covering a small percentage of cell area. Control: n = 22 cells, 5 slices, 5 mice. RuBi-DA: n = 720 cells, 11 slices, 8 mice.




**Figure 5. Fast astrocyte responses to DA in PFC slices occur via  $\alpha$ 1-ARs**

(A) Schematic for RuBi-DA uncaging and simultaneous 2P  $\text{Ca}^{2+}$  imaging in PFC slices bathed with receptor antagonists.

(B)  $\text{Ca}^{2+}$  increases shortly after RuBi-DA uncaging (control), an effect blocked by  $\alpha$ 1-AR antagonist doxazosin (10  $\mu\text{M}$ ) but not by D1 (SCH23390, 10  $\mu\text{M}$ ), D2 (sulpiride, 0.5  $\mu\text{M}$ ),  $\alpha$ 2-AR (Idazoxan, 10  $\mu\text{M}$ ), or  $\beta$ -AR (propranolol, 10mM) antagonists. Data relative to uncaging (blue lines,  $t = 0$ ) as slice average traces (gray lines) of AQuA-detected, Z scored  $\text{Ca}^{2+}$  events in GCaMP6f-expressing astrocytes, with overall mean as colored traces.

(C) Quantification of (B), shown as 30-s mean of slice  $\text{Ca}^{2+}$  immediately before (white) or after RuBi-DA uncaging (blue) in presence of inhibitors. Slices (gray lines) and corresponding mean  $\pm$  SEM (black lines, solid dots, and error bars):  $0.03 \pm 0.10$ ,  $1.08 \pm 0.17$  (control);  $0.07 \pm 0.07$ ,  $0.83 \pm 0.06$  (D1);  $0.02 \pm 0.10$ ,  $1.21 \pm 0.20$  (D2);  $0.39 \pm 0.10$ ,  $0.47 \pm 0.09$  ( $\alpha$ 1);  $-0.03 \pm 0.06$ ,  $0.82 \pm 0.15$  ( $\alpha$ 2);  $0.19 \pm 0.12$ ,  $1.09 \pm 0.21$  ( $\beta$ ). Paired t test after Anderson-Darling test to compare pre- with post-uncaging values; \* $p < 0.05$ , \*\* $p < 0.01$ ;  $p = 0.004$  (control), 0.0006 (D1), 0.008 (D2), 0.624 ( $\alpha$ 1), 0.008 ( $\alpha$ 2), 0.036 ( $\beta$ );  $n = 6-9$  slices, 5-9 mice. Pre-uncaging values in treatments versus control were not statistically different (Kruskal-Wallis test with Dunn's correction: adjusted  $p > 0.19$  for all comparisons).



### Figure 6. Astrocyte $\text{Ca}^{2+}$ follows DA release *in vivo* via $\alpha 1$ -ARs

(A) Left: schematic for dual-color FP in PFC of behaving mice for DA (dLight1.2, green) and astrocyte  $\text{Ca}^{2+}$  (jR-GECO1b, magenta). Right: example traces during aversive tail lift (triangles).

(B) Average FP traces for DA and  $\text{Ca}^{2+}$  in PFC, aligned to  $\text{Ca}^{2+}$  transient onsets. Mean  $\pm$  SEM;  $n = 96$  transients, 9 mice.

(C) Response amplitude for DA (green) and  $\text{Ca}^{2+}$  (magenta) in aversive stimulation experiments deviate from baseline values (dLight:  $0.89 \pm 0.04$  dF/F; jR-GECO:  $0.31 \pm 0.04$  dF/F). Tukey boxplots, calculated as maximum dF/F relative to 20-s mean before the jR-GECO peak. One-sample t test or sign test with hypothesized mean 0, after Anderson-Darling test to show difference from 0;  $***p < 0.001$ ;  $n = 96$  transients, 9 mice.

(D) Cross-correlation of dLight and jR-GECO traces (left) indicates that DA signals *in vivo* precede astrocyte  $\text{Ca}^{2+}$  transients by  $1.4 \pm 0.2$  s (right). Mean  $\pm$  SEM and Tukey boxplots; one-sample sign test with hypothesized mean 0,  $***p < 0.001$ ;  $n = 96$  transients, 9 mice.

(E) Schematic of dual-color FP in PFC of mice treated with the LC-toxin DSP4 (50 mg/kg, intraperitoneally [i.p.], 2 injections, 2 days apart), before and after administration of  $\alpha 1$ -AR antagonist prazosin (5 mg/kg, i.p.).

(F) LC inputs to PFC revealed by NET staining (top, naive) are decreased after DSP4 (bottom).

(G) In NE-depleted animals, DA transients in PFC (left, dLight) during aversive stimulation are still present (DSP4, orange;  $1.02 \pm 0.11$  dF/F) and unaffected when  $\alpha 1$ -ARs are blocked (+prazosin, aqua;  $0.77 \pm 0.05$ ), whereas  $\text{Ca}^{2+}$  peaks (right, jR-GECO) are significantly reduced by prazosin (DSP4:  $0.11 \pm 0.01$  dF/F; +prazosin:  $0.04 \pm 0.0$  dF/F), indicating that PFC  $\text{Ca}^{2+}$  relies on  $\alpha 1$ -ARs even with diminished NE. Tukey boxplots, calculated as maximum dF/F relative to 20-s means before jR-GECO peaks. Wilcoxon rank-sum test;  $***p = 0.0003$ ;  $n = 27$ – $29$  transients, 4 mice.

(H) Cross-correlation of dLight and jR-GECO traces (left) in NE-depleted animals (DSP4) and in the same animals after inhibition of  $\alpha 1$ -ARs (DSP4 + prazosin) shows that DA signals in PFC precede  $\text{Ca}^{2+}$  with diminished NE (DSP4,  $-2.64 \pm 0.52$  s) but not after


inhibition of  $\alpha_1$ -ARs (+prazosin,  $0.73 \pm 0.65$  s). Trace mean  $\pm$  SEM and Tukey boxplots; Wilcoxon rank-sum test; \*\*\* $p = 0.0003$ ;  $n = 27-29$  transients, 4 mice.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 7. DA mobilizes extracellular ATP at discrete locations at PFC astrocytes via  $\alpha_1$ -ARs**

(A) Schematic for 2P astrocytic GRAB<sub>ATP</sub> imaging in acute PFC slices.

(B–C) Continuous bath application of ATP (50  $\mu$ M) induces strong, sustained fluorescent signals in astrocytes, shown as (B) PFC astrocytes expressing GRAB<sub>ATP</sub> (grayscale) with color overlay of AQuA-detected ATP events before (left, basal) and after ATP (right), and (C) time course of the dF/F amplitude of AQuA-detected ATP events relative to exogenous ATP application ( $t = 0$ ). Mean  $\pm$  SEM of slice traces  $n = 52/62$  active/total cells, 8 slices, 3 mice.

(D) GRAB<sub>ATP</sub> event rate increases following ATP stimulation. Slice averages (lines) and mean  $\pm$  SEM (dots and error bars):  $0.0007 \pm 0.0007$  (basal),  $0.010 \pm 0.001$  (+ATP)  $\text{min}^{-1}$ . Paired t test after Anderson-Darling test; \*\*\* $p < 10^{-4}$ ;  $n = 8$  slices, 3 mice.

(E) GRAB<sub>ATP</sub> events in response to continuous ATP application covered the entire astrocyte territory (left,  $1,044 \pm 224 \mu\text{m}^2$ ) and were sustained (right,  $100 \pm 16$  s). Slice averages of active cells (transparent dots) and overall mean  $\pm$  SEM (solid dots and error bars);  $n = 8$  slices, 3 mice.

(F–H) Application of DA (10  $\mu$ M) (F) induces localized ATP events, shown as (G) GRAB<sub>ATP</sub> micrographs and AQuA overlay, which are delayed (H) relative to DA application ( $t = 0$ ). Mean  $\pm$  SEM of slice averages  $n = 23/101$  active/total cells, 10 slices, 5 mice.

(I) ATP event rate after DA application was higher than baseline. Slice averages (lines) and mean  $\pm$  sem (dots and error bars):  $0.0007 \pm 0.0004$  (Basal),  $0.005 \pm 0.001$  (+DA)  $\text{min}^{-1}$ . Paired t test after Anderson-Darling test; \*,  $p = 0.025$ ;  $n = 10$  slices, 5 mice.



(J) GRAB<sub>ATP</sub> events in response to DA were smaller than entire astrocyte territories ( $221 \pm 52 \mu\text{m}^2$ ) and time restricted ( $30 \pm 8 \text{ s}$ ). Slice averages of active cells (transparent dots) and overall mean  $\pm$  SEM (solid dots and error bars);  $n = 9$  slices, 5 mice.

(K–M) In presence of  $\alpha_1$ -AR antagonist doxazosin ( $10 \mu\text{M}$ ), DA (K) does not induce a change in ATP<sub>E</sub> events, as shown by (L) GRAB<sub>ATP</sub> micrographs and AQuA overlay, and (M) time course of GRAB<sub>ATP</sub> event dF/F relative to DA application ( $t = 0, 10 \mu\text{M}$ ). Mean  $\pm$  SEM of slice averages (line and shaded area).  $n = 41/160$  active/total cells, 10 slices, 5 mice.

(N) In presence of doxazosin, DA application does not increase ATP<sub>E</sub> event rate. Slice averages (lines) and mean  $\pm$  SEM (dots and error bars):  $0.0028 \pm 0.0008$  (basal),  $0.0026 \pm 0.0005$  (+Dox/+DA)  $\text{min}^{-1}$ . Paired t test after Anderson-Darling test; n.s.,  $p = 0.878$ ;  $n = 10$  slices, 5 mice.

(O) GRAB<sub>ATP</sub> events in presence of doxazosin are similar in size ( $267 \pm 53 \mu\text{m}^2$ ) and duration ( $48 \pm 20 \text{ s}$ ) to those observed in DA alone. Slice averages of active cells (transparent dots) and overall mean  $\pm$  SEM (solid dots and error bars);  $n = 10$  slices, 5 mice.

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Chicken anti-GFP	Aves Lab	Cat#GFP-1020; RRID:AB_2307313
Rat anti-GFAP	Thermo Fisher Scientific	Cat#13-0300; RRID:AB_2532994
Rat anti-mCherry	Thermo Fisher Scientific	Cat#M11217; RRID:AB_2536611
Mouse anti-NET	MAb Technologies	Cat#NET05-2; RRID:AB_2571639
Goat anti-chicken Alexa Fluor 488	Thermo Fisher Scientific	Cat#A-11039; RRID:AB_2534096
Goat anti-mouse Alexa Fluor 555	Thermo Fisher Scientific	Cat#A-21422; RRID:AB_2535844
Goat anti-rat Alexa Fluor 555	Thermo Fisher Scientific	Cat#A-21434; RRID:AB_2535855
<b>Bacterial and virus strains</b>		
AAV9-CAG-dLight1.2	Patriarchi et al. (2018); Tian lab (UC Davis, USA)	N/A
AAV5-GfaABC <sub>1</sub> D-GCaMP6f-SV40	UPenn Vector Core	Lot#v6486S, Lot#v6772S
AAV5-GfaABC <sub>1</sub> D-Lck-GCaMP6f-SV40	UPenn Vector Core	Lot#v6287S
AAV9-GfaABC <sub>1</sub> D-Lck-jRGECO1b	UPenn Vector Core	Lot#225
AAV9-hGfap-pinkFlamindo	Harada et al. (2017); Hirase lab (University of Copenhagen, Denmark)	N/A
AAV9-hSyn-ATP1.0 (GRAB <sub>ATP</sub> )	Wu et al. (2021); Li lab (Peking University, China)	N/A
AAV5-hSyn-dLight1.2	Patriarchi et al. (2018)	Addgene Cat#111068-AAV5
AAV9-hSyn-NE2.1 (GRAB <sub>NE</sub> )	Vigene Biosciences	Cat#h-N01, Lot#2018.6.7
<b>Chemicals, peptides, and recombinant proteins</b>		
AM251 (CB1 antagonist)	Tocris	Cat#1117; CAS: 183232-66-8
CGP 55845 hydrochloride (GABA <sub>B</sub> antagonist)	Tocris	Cat#1248; CAS: 149184-22-5
CGS 15943 (adenosine receptor antagonist)	Tocris	Cat#1699; CAS: 104615-18-1
Dopamine hydrochloride	Tocris	Cat#3548; CAS: 62-31-7
Doxazosin mesylate ( $\alpha$ 1-AR antagonist)	Tocris	Cat#2964; CAS: 77883-43-3
DSP-4 (adrenergic neurotoxin)	Sigma Aldrich	Cat#C8417; CAS: 40616-75-9
Forskolin (AC activator)	Tocris	Cat#1099; CAS: 66575-29-9
Idazoxan hydrochloride ( $\alpha$ 2-AR antagonist)	Sigma Aldrich	Cat#I6138; CAS: 79944-56-2
Ipratropium bromide (muscarinic antagonist)	Tocris	Cat#0692; CAS: 22254-24-6
LY 341495 disodium salt (mGlu <sub>1-8</sub> antagonist)	Tocris	Cat#4062; PubChem ID: 90488907
Phentolamine mesylate ( $\alpha$ AR antagonist)	Tocris	Cat#6431; CAS: 65-28-1
PPADS tetrasodium salt (purinergic antagonist)	Tocris	Cat#0625; CAS: 192575-19-2
Prazosin hydrochloride (bioavailable $\alpha$ 1-AR antagonist)	Sigma Aldrich	Cat#P7791; CAS: 19237-84-4
(S)-(-)-Propranolol hydrochloride ( $\beta$ AR antagonist)	Tocris	Cat#0834; CAS: 4199-10-4
(-)-Quinpirole hydrochloride (D <sub>2/3/4</sub> agonist)	Tocris	Cat#1061; CAS: 85798-08-9
RiBi-Dopa (caged dopamine)	Araya et al. (2013); Abcam	Cat#ab143462; PubChem ID: 90488992
SCH23390 (D <sub>1/5</sub> antagonist)	Tocris	Cat#0925; CAS: 125941-87-9
SKF 38393 hydrobromide (D <sub>1/5</sub> agonist)	Tocris	Cat#0922; CAS: 20012-10-6

REAGENT or RESOURCE	SOURCE	IDENTIFIER
SKF 81297 hydrobromide (D <sub>1/5</sub> agonist)	Tocris	Cat#1447; CAS: 67287-39-2
(S)-(-)-Sulpiride (D <sub>2/3/4</sub> antagonist)	Tocris	Cat#0895; CAS: 23672-07-3
Tetrodotoxin citrate (Na <sup>+</sup> channel blocker)	Hello Bio	Cat#HB1035; CAS: 18660-81-6
Experimental models: Organisms/strains		
Mouse: Aldh111-Cre/ERT2: B6N.FVB-Tg (A dh1 1-cre/ERT2)1Khakh/J	Srinivasan et al. (2016); Khakh lab (UCLA, USA)	MGI:5806568; RRID:IMSR_JAX:031008
Mouse: Aldh111-EGFP: Tg(A dh1 1-EGFP) OFC789Gsat/Mmucd	Gong et al. (2003); Gensat founder line: OFC789	MGI:3843271; RRID:MMRRC_011015-UCD
Mouse: Aldh111-tdTomato: Tg(A dh1 1-tdTomato)TH6Gsat/Mmucd	Gong et al. (2003)	MGI:5435489; RRID:MMRRC_036700-UCD
Mouse: Drd1a-tdTomato: FVB.Cg-Tg (Drd1-tdTomato)5Calak/Mmnc	Shuen et al. (2008)	MGI:4360387; RRID:MMRRC_030512-UNC
Mouse: Drd2-EGFP: Tg(Drd2-EGFP) S118Gsat/Mmnc	Gong et al. (2003); Bender lab (UCSF, USA)	MGI:3843608; RRID:MMRRC_000230-UNC
Mouse: IP <sub>3</sub> R <sup>2-/-</sup> : <i>Itpr2</i> -deficient	Li et al. (2005); Dr. Katsuhiko Mikoshiba (RIKEN, Japan)	N/A
Mouse: Lck-GCaMP6 <sup>fl/fl</sup> ; C57BL/6N- <i>Gt(ROSA)26Sor<sup>tm1</sup>(CAG-GCaMP6f)Khakh/J</i>	Srinivasan et al. (2016); Khakh lab (UCLA, USA)	MGI:5806654; RRID:IMSR_JAX:029626
Mouse: OCT3 <sup>-/-</sup> : <i>Slc22a3<sup>tm1Dpb</sup></i> , targeted mutation 1, Denise P Barlow	Zwart et al. (2001); Irannejad lab (UCSF, USA)	MGI:2388117
Software and algorithms		
Astrocyte Quantification and Analysis (AQuA)	Wang et al. (2019)	<a href="https://github.com/yu-lab-vt/AQuA">https://github.com/yu-lab-vt/AQuA</a>
Fluo-4 fluorescence analysis (CaTracer 3 Beta)	Poskanzer and Yuste (2016)	<a href="http://blogs.cuit.columbia.edu/rmy5/files/2018/02/caltracer3beta.zip">http://blogs.cuit.columbia.edu/rmy5/files/2018/02/caltracer3beta.zip</a>
Interactive wand segmentation tool	SCF-MPI-CBG plugin	<a href="https://sites.imagej.net/SCF-MPI-CBG/">https://sites.imagej.net/SCF-MPI-CBG/</a>
Motion Correction ImageJ plugin (MoCo)	Dubbs et al. (2016)	<a href="https://github.com/NTCColumbia/moco">https://github.com/NTCColumbia/moco</a>
FP preprocessing (custom written code in MATLAB)	Tucker-Davis Technologies	<a href="https://www.tdt.com/docs/sdk/offline-data-analysis/offline-data-python/FibPhoEpoAveraging">https://www.tdt.com/docs/sdk/offline-data-analysis/offline-data-python/FibPhoEpoAveraging</a>
Other		
GRIN lenses for 2P-imaging in PFC (1-mm diameter, 4.38-mm length, WDA 100, 860 nm)	Inscopix	Cat#130-000895
Fiber optic cannula for Fiber Photometry in PFC	Doric Lenses	Cat#MFC_400/430-0.48_2.8mm_ZF1.25_FLT
Optoswitch to monitor locomotion speed	TT Electronics, Newark	Cat#OPB800L5